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Abstract 
In June of 2015, 27,378 of the 28,000 returning Operation Iraqi 
Freedom/Operation Enduring Freedom (OIF/OEF) veterans report being exposed to burn 
pits.  According to Barth et al. (2014), 9,660 returning OIF/OEF veterans were diagnosed 
with respiratory diseases, to include asthma, bronchitis, and sinusitis, thus strengthening 
the need to develop decision support tools that can be used to understand the relationships 
between chemical exposure and disease.  In this study an Artificial Neural Network 
(ANN) was used to predict the chemical-disease associations for burn pit constituents.  
Ten burn pit constituents were tested using varying hidden layers, similar chemical 
structure relationships, and three Training, Validation, and Testing (TVT) ratios.  The 
ANN predicted misidentification rates of 73% or greater when the hidden layer size 
varied between 1 and 5.  Misidentification rates of 75% or greater were observed for 
ANN simulations when the TVT ratios ranged from 60/20/20 to 80/10/10.  ANN-based 
screening of chemical groups containing chemicals with benzene rings and chemicals 
containing hydrocarbon chains produced misidentification rates of 73% or greater, and R2 
values of 0.0762 and lower.  Hidden Layer size, TVT ratios, and chemical structure had 
little effect on the model’s performance; additional training data is needed to improve the 
predictive capability of the ANN.  The ANN-based screening of individual burn pit 
constituents produced several chemicals with R2 values greater than 0.8.  These 
chemicals have been prioritized to further develop predictive ANN models for human 
health force support, resulting in the first research screening burn pit constituents with an 
ANN, and the first to prioritize burn pit emissions for future testing. 
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USING ARTIFICIAL NEURAL NETWORKS TO PREDICT DISEASE 
ASSOCIATIONS FOR CHEMICALS PRESENT IN BURN PIT EMISSIONS 
  
I.  Introduction 
1. General Issue 
The risks associated with industrial use chemicals are reduced as a result of the 
performance of risk assessments.  Establishing risk associated with a chemical 
involves the identification of the hazard, a hazard assessment, an exposure 
assessment, and basic characterization of the risk, resulting in the generation of 
effects caused by chemical exposure.  According to the American Chemical Society 
(ACS), chemical risk assessments cannot be accomplished using a single set of 
analytical tests.  Instead, a chemical risk assessment should involve a process for 
selecting the most appropriate method to evaluate the impacts associated with the life 
cycle exposure to a chemical (ACS, 2015).   
Due to the evolving nature of the military-related missions overseas, risk 
assessments are often performed post-hoc.  The highly publicized post-hoc burn pit 
assessments have sparked a need for military chemical risk assessment reform.  As a 
result of the risk assessment reform, this thesis will explore the diseases that are 
linked to the constituents present in burn pit emissions.  The research involved in this 
thesis focused on studying the relationship between chemicals and disease, burn pit 
emission constituents, and the use of an Artificial Neural Network (ANN) to predict 
chemical-disease associations among burn pit constituents.    
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a. The relationship between chemicals and disease 
i. Etiology 
The etiology of disease has many facets.  One facet involves 
studying gene-environment interactions that mediate, change, or alter 
gene function (Liu et al., 2008).  Environmental exposure to 
chemicals may influence biological system interaction.  By studying 
chemical-biological system interaction insight may be provided into 
a chemical’s mechanism of action, potential toxicity, and individual 
disease susceptibility.   
ii. Mechanism of Action and Biomarkers 
In pharmacology, the term Mechanism of Action (MOA) is 
referred to as the specific biochemical interaction in which a 
substance produces an effect or biomarker.  Characterizing a 
chemical mechanism of action will allow for the identification of the 
chemical biomarkers (Heinzel et al., 2014).  A biomarker is a 
measurable cellular, biochemical, or molecular alteration in human 
tissues, cells, or fluids that are indicative of biological processes, 
biological responses, or conditions (Mayeux, 2004).  There are 
various types of biomarkers: genomic, transcriptomic proteomic, and 
metabolomic, which can be used as prognostic, predictive, or 
pharmacodynamic indicator.  By studying biomarkers, and the 
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body’s biological indicator of exposure, scientists are able to link 
chemical exposure to predictive health outcomes.  
iii. Epigenetics 
According to Liu et al. (2008), gene-environment interaction gives 
rise to epigenetic changes of the genome in response to a change in 
the environment.  The gene-environment interaction may result in 
the alteration of gene operation, the formation of disease, and/or 
gene mutation. 
iv. Chemical Structure 
Chemical bonding results in a substance having unique physical 
and chemical properties.  The number and type of chemical bonds 
determines the compound’s structure, connectivity, and geometry.  
These unique properties have the ability to influence biological 
activity, specifically the toxicity of a compound (Vouk et al., 1987).  
Structure-activity relationships (SARs) have been used to describe a 
chemical’s ability to induce adverse health effects (Vouk et al., 
1987). 
b. Burn Pits 
Proper disposal of waste during in Afghanistan and Iraq have been 
essential in preventing unsanitary conditions and health hazards.  When 
sanitary and waste management facilities are unavailable, military forces have 
relied on waste burning in the form of open-air burn pits as a method to 
reduce the volume of waste.  Air emissions from open-air burn pits release 
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pollutants such as dioxins, particle matter (PM), polycyclic aromatic 
hydrocarbons (PAHs), and volatile organic compounds (VOCs) directly into 
the atmosphere (EPA, 2002).  Current research conducted by the United States 
(US) Environmental Protection Agency (EPA) has found an increased risk of 
heart disease, asthma, and emphysema associated with the inhalation of air 
emissions from burning trash.  In contrast, the health risks associated with 
military-related burn pit exposures have not been thoroughly assessed.     
In response to service member concerns, an environmental health risk 
assessment was accomplished in 2007 in an attempt to characterize burn pit 
emissions.  Initial screening samples, risk assessment models, and airborne 
concentration calculations performed were reported to the Department of 
Defense (DOD) Defense Health Board (DHB).  The composite risk estimate 
performed compared burn pit air sampling result values to the one-year 
military exposure guidelines (MEGs), evaluated the severity of health risks, 
along with the probability and frequency of the exposure occurring.  The risk 
estimate determined that exposures to volatile organic compounds (VOCs), 
polycyclic aromatics hydrocarbons (PAHs), dioxins, and furans were 
considered low (Weese, 2010).  The health risk assessment rating of “low” 
was provided to commanders and the DHB in 2007.   
The DHB determined that several problems existed with risk assessment, 
to include the infrequency of detection and sampling of burn pit emissions.   
Furthermore, the data presented to the DHB from Joint Base Balad (JBB) Iraq 
burn pit sampling employed quantitative screening using the Human Health 
          
5 
Risk Assessment Guidance for Superfund methodology outlined by the EPA.  
The EPA Methodology compared values designed for long-term exposure 
scenarios regarding a general population that included children and the 
elderly.  Service member cancer risks were also estimated using theoretical or 
probabilistic cancer risk estimates and the service member’s time on the base.  
The time periods used in the risk estimate included 24-hour days, seven days 
per week for twelve-month, four-month, and one-month exposure increments.  
The EPA method determined that both non-cancer and cancer risks were 
acceptable and considered safe per EPA classification (Weese, 2010).  
According to the DHB, the report offered limited data examination and 
information on the potential effects of burn pit combustion exposures.   
Neither the amount, nor the type of material disposed of in the burn pits, was 
well controlled, defined, or characterized—thus resulting in the DHB 
believing that the burn pit emissions were not fully characterized.  Fearing 
that burn pit combustion products pose an inhalation hazard that can 
potentially increase the long-term health risks for exposed service members, a 
need arose to characterize the gaps in procedure and determine risk-
assessment practices, which could be effectively employed in austere and 
hostile environments (DHB, 2008). 
As multiple complaints arose from veteran service members regarding 
burn pit exposures, so has the need to characterize the emissions and 
exposures from open air burn pits.  In 2010, 300 veteran service members 
joined a class-action lawsuit against Kellogg Brown and Root (KBR), a 
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military contractor that operated several burn pits at bases in Iraq (NY Times, 
2010).  In response to the growing concern for service-members’ exposure to 
harmful contaminants from open burn pits, and increases in respiratory 
illnesses in returning veterans, Congress and the Department of Veterans 
Affairs (VA) were directed to conduct studies which would determine the 
long-term health effects from open-air burn pit operations (IOM, 2011).  At 
the same time, the Armed Forces Health Surveillance Center (AFHSC) and 
the Naval Health Research Center (NHRC) were tasked to conduct 
epidemiologic studies to determine any associations between burn pit 
emissions and exposure-related illnesses (Armed Forces Health Surveillance 
Center, Naval Health Research Center and US Army Public Health Command, 
2010).  Later, the VA commissioned the Institute of Medicine (IOM) to assess 
the long-term health effects from exposure to burn pits in Afghanistan and 
Iraq (IOM, 2011).   
The IOM committee used the burn pit at Joint Base Balad (JBB) Iraq as 
the basis of their study to assess the long-term health effects from exposure to 
burn pits.  To aid in the IOM study, the DOD provided raw air-sampling data, 
which were used to determine which chemicals were present at JBB, and 
which chemicals were present in ambient air.  Based on this data, the 
committee found that levels of most pollutants at JBB were not higher than 
the levels measured at other polluted sites worldwide.  However, IOM found 
insufficient evidence that prevented the committee from developing firm 
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conclusions regarding the long-term health effects caused by burn pit 
exposures.  
c. Artificial Neural Networks and predictive modeling 
An Artificial Neural Network (ANN) is a computational model based on 
the neural structure of a human brain.  ANNs are comprised of interconnected 
processing elements or neurons that are trained to solve specific problems.  As 
a nonlinear statistical data-modeling tool, ANNs establish relationships 
between an input and an output and models the result.  Results from a study 
performed by Brouch (2014) provided the foundation that ANNs may have 
the potential to predict chemical-disease associations.  
2. Problem Statement 
The Comparative Toxicogenomics Database (CTD) is a publicly available 
database that integrates scientific literature to understand how environmental 
chemical exposures affect human health.  The CTD organizes, integrates, and 
maintains data illustrating the interactions between chemicals and genes, chemicals 
and proteins, chemicals and disease, and genes and diseases (Davis et al., 2014).  The 
organization, integration, and maintenance of chemical data by the CTD results in the 
data being classified as curated.  However, current sampling of mock burn pit 
emissions identified several constituents that currently lack research and data.  The 
lack of current research and data constitutes that these constituents be classified as 
uncurated.  It is hypothesized that an ANN, coupled with current and relevant 
literature on uncurated burn pit constituents could map uncurated constituents to 
diseases across a wide variety of test species. 
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3. Research Objectives 
a. Determine the effect of Hidden Layers (HL) on ANN performance for 
constituents relevant to burn pit emissions. 
b. Determine the effect of Training, Validation, and Testing (TVT) ratios on 
ANN performance for constituents relevant to burn pit emissions. 
c. Determine the effect of chemical structure on ANN performance for 
constituents relevant to burn pit emissions. 
d. Identify key data gaps needed to advance ANN-based screening of 
constituents relevant to burn pit emissions. 
4. Research Focus 
The focus of this research is to predict the long-term health effects of uncurated 
burn pit emission constituents and verify ANN chemical-disease predictions with 
current and relevant literature.  Using current literature, data and informational gaps 
on the uncurated burn pit constituents will be determined.  The identified 
informational gaps will institute the need for further research in order to establish 
relationships between constituents, mechanisms of action, biomarkers, and disease.  
5.  Methodology 
Utilizing the mock burn pit constituent analysis performed by Woodall (2012), the 
47 constituents identified in the mock burn pit analysis were assessed using the CTD 
to verify curation status.  Of the 47 constituents, ten constituents were determined to 
be uncurated.  A curation of the ten uncurated chemicals was conducted to garner 
possible chemical-disease associations.  Using the ANN established by Brouch 
(2014), the ANN was modified and tested using the ten uncurated constituents and the 
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disease associations curated during the literature review.  Using the uncurated 
constituents, three tests were accomplished to determine the optimal ANN 
performance standards.  The first test studied the effect of Hidden Layers (HL) on 
ANN performance.  The second test was performed with three different TVT ratios, 
which were then compared to determine their effect on the ANN performance.  The 
third test performed determined if chemicals with similar structures had an effect on 
the performance of the ANN.  The culmination of all three tests established standard 
protocol for analyzing uncurated constituents.  
6. Limitations 
a. As the number of HL increased, the ANN response time slowed.  This delay 
in response time indicated that the ANN had an optimal HL size.  Five HL 
sizes were selected and tested.  Three of the five tests demonstrated positive 
response times.  Due to time limitations, only one of the three positive 
response times was selected and further evaluated.   
b. In order to test and train the ANN, research was conducted to determine the 
current diseases associated with each constituent.  If a constituent was found 
to have only two associated diseases then the model would be trained and 
tested to associate only two random diseases.  Since uncurated constituents 
have minimal research accomplished for them, it is presumed that uncurated 
constituents may have more disease associations then those tested in this 
thesis.   
c. This work did not track specific animal species disease-chemical associations.  
All known animal species disease-chemical associations were used as input 
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into the ANN regardless of their animal species pairing.  However, animal 
species associations may be mapped to disease-chemical pairings using 
ANNs. 
d. Relevant research on the uncurated constituents is limited to the availability of 
research, testing, and evaluation for each one of the uncurated constituents. 
e. The CTD maintains limited data on chemical mixtures and the synergistic 
effects from chemical exposure. 
7. Implications 
Chemical exposure effects are determined through extensive and costly research, 
testing, and evaluation.  The focus of this thesis is to refine a previous-established 
ANN to garner an alternative method for determining chemical exposure effects.  
This alternative may reduce the time and costs needed to research, test, and evaluate 
chemical hazards.  The refined ANN may also serve as a decision support tool for 
military commanders, when faced with operations that involve the use of chemical 
hazards.   
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II. Literature Review 
1. Relevant Research 
a. The Relationship between chemicals and disease 
i. Etiology:  
This thesis focuses on establishing the need to understand how 
environmental agents influence disease.  Through genomic and toxicological 
studies, scientists and researchers have established that chemicals have the 
ability to mutate, alter, and interact with genes often influencing gene 
expression and protein function (Lane, 2002).  The effects of chemical 
compounds must be further characterized to understand the biochemical and 
genetic complexity that the chemical imposes on cells, tissues, organs, and 
overall human health.    
In order to characterize a chemical’s impact, the Environmental Protection 
Agency (EPA) uses chemical risk assessments to elucidate the human health 
and ecological risks from chemical hazards.  As of 2015, the EPA reported 
approximately 85,000 chemicals listed on the Toxic Substance Control Act 
(TSCA) Inventory (EPA, 2015).  Annually, the EPA receives 400 new Notice 
of Commencements (NOC) for chemicals that may modify the TSCA 
inventory.  Due to the amount of NOCs received by the EPA, the EPA has 
identified data gaps in the evaluation of chemicals.  These data gaps include; 
chemical use, exposure pathways, and toxicity data.  The significance of the 
missing data prevents chemical risk assessments from being accomplished.   
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The data gaps identified by the EPA, and the absence of chemical risk 
assessments, established a need for alternate methods when performing 
chemical risk assessments.  As an alternative method to understand how 
environmental chemicals affect human health, North Carolina State University 
(NCSU) developed the Comparative Toxicogenomics Database (CTD).  The 
CTD commenced a curation or data collection of environmental chemicals 
(Mattingly et al., 2003).  The CTD established a collaborative database with 
curated chemical data describing the relationships between chemicals, genes, 
proteins, and human diseases to advance the understanding of chemical effects 
on human health.  The CTD integrates all data to facilitate the construction of 
chemical-gene-disease network and provide the groundwork for investigating 
the molecular basis of chemical-disease associations and toxicity (Davis et al., 
2008).  
Despite the extensive construction and curation of data provided by the 
CTD, many chemicals remain uncurated.  Uncurated chemical data is absent 
of gene-interactions despite disease association, mechanisms, or biomarker 
associations.  Due to the data gaps, relevant information is missing that would 
otherwise help understand the basis of disease.  Despite containing uncurated 
data, the CTD contains the tools needed to generate testable hypotheses 
regarding the underlying etiology of chemical-disease relationships (Davis et 
al., 2015).   
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ii. Mechanisms of Action/Mode of Action and Epigenetics:  
A Mode of Action (MoA) describes a cellular functional or anatomical 
change resulting from environmental exposure (FDA, 2011).  In comparison, 
a Mechanism Of Action (MOA) is used in pharmacology to describe 
biochemical interaction at the molecular level.  The Federal Food, Drug, and 
Cosmetic (FD&C) Act (2016) interprets chemical action through either 
chemical reaction or intermolecular forces or both.  Chemical action either 
results in a bodily response at the cellular or molecular level or when the 
chemical binds with or modifies a molecular target or receptor.  
Identifying the effect of exposure on human health is a major objective of 
biomedical research.  In environmental health studies, it is recognized that 
environmental exposure could produce Deoxyribonucleic Acid (DNA) 
mutations.  As a consequence of DNA mutation, chemical substances have 
been categorized according to their ability to alter DNA (Pulliero et al., 2015).  
A chemical’s ability to alter DNA established a fundamental effort to 
determine risk assessment procedures, prevention, exposure reduction, and 
regulatory efforts. 
Unlike the chemical substances that cause, or are suspected to cause, DNA 
mutation, there are chemical substances that cause gene expression and 
heritable change without changing or mutating the DNA sequence.  The study 
of heritable change and gene expression is called epigenetics.  Epigeneticist’s 
investigate heritable changes in gene expression occurring through the 
mechanisms of DNA methylation, histone modification, and microRN 
          
14 
expression (Hou et al., 2012).  In vitro, animal, and human studies performed 
by Baccarelli and Bollati (2009) have identified several classes of 
environmental chemicals that modify epigenetic mechanisms resulting in the 
identification of epigenetic mechanisms that may mediate specific 
mechanisms of toxicity and specific chemical response.   Various chemical 
mechanism/mode of action are understood, others remain unidentified.  
 Baccarelli and Bollati (2009) reported that certain chemical exposures had 
altered epigenetic mechanisms, and that the same or similar epigenetic 
alterations were found in patients with the disease of concern or in diseased 
tissue.   However, it was not determined whether the exposed individual’s 
developed epigenetic alterations over time or which alterations increase the 
risk of developing disease.  Forgoing the identification of these factors 
increased the difficulty in establishing the chemical-disease relationship 
between the chemical, the epigenetic change, and the presence of disease.  At 
this time, very little is known about which epigenetic alterations are part of 
normal variability and which alterations are considered adverse.  In order to 
understand epigenetic variability and the potential for chemicals to induce 
epigenetic modifications or alterations, an understanding of the chemical’s 
mode of action (MoA)/mechanism of action (MOA) is needed.  
A workshop held by the National Academy of Sciences’ (NAS) Standing 
Committee on the Use of Emerging Science for Environmental Health 
Decisions discussed the role of chemically induced epigenetic changes in 
regulatory and policymaking decisions.  The committee concluded that 
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epigenetic testing is not sufficiently validated for inclusion into any regulatory 
process.  At this time, there is not a single/uniform test for epigenetic effects.  
Without understanding epigenetic effects, the patterns, variability, and long-
term health effects relating to epigenetic changes are not well understood.  As 
part of the committee’s recommendations, there remains a need to establish a 
tiered epigenetic screening process to prioritize chemicals for further 
epigenetic analysis (Adler, 2010).  
iii. Biomarkers:  
Silins and Hogberg (2011) divide the use of biomonitoring into three 
classes that measure biological markers of exposure, effect, and susceptibility.   
Where, biomarkers of exposure measure the parent compound, the parent 
compound’s metabolites, the biologically effective dose, and the biological 
effect (Silins and Hogberg, 2011; WHO, 2011).  Silins and Hogberg (2011) 
identified biomarkers of effect as the cellular changes that alter expression of 
metabolic enzymes and disease development, at the same time the World 
Health Organization (WHO) (2011) identifies biomarkers of effect as 
structure alteration, altered function, or clinic disease.  Lastly, the biomarker 
of susceptibility indicates the ability of an individual to respond to an 
environmental exposure (WHO, 2011). 
Traditionally, the EPA and other federal agencies characterize 
environmental risk by extrapolating a chemical dose from in vitro and in vivo 
toxicological studies.  According to Shatkin and Ranalli (2007), the use of 
biomonitoring will refine the risk characterization procedure by providing an 
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understanding of the fate and behavior of a chemical once inside the body.  
The use of biomonitoring may validate, improve, and alter future 
pharmacokinetic modeling, clinical applications, and toxicogenomic 
applications (Shatkin and Ranalli, 2007).  
Currently, biomonitoring is used in both clinical and toxicogenomic 
applications.  In clinical applications, biomonitoring is used to characterize 
exposures that occur in the occupational environment.  It is believed that 
biomonitoring data can measure and assess environmental exposure trends, 
which assists with defining the relationship between exposure and disease.  
Biomonitoring may also provide an employee baseline prior to exposure.   
In toxicogenomic applications, data from toxicogenomic studies are 
compared with in vitro cellular studies to identify chemical toxicity 
mechanisms.  Utilizing exposure measurements, gene expression changes, and 
traditional toxicological markers, the identification of chemical toxicity 
mechanisms has been processed.  The chemical toxicity mechanisms can then 
be used to generate biomarkers related to chemical exposure, chemical effect, 
or individual susceptibility (McHale et al., 2010).  Similarly, the European 
Commission (EU) funded a research project on gene expression analysis and 
its use in relating biomonitoring to environmental carcinogenic exposures 
(Van Leeuwen et al., 2008). Van Leeuwen et al. (2008) consider the use of 
biological monitoring and biomonitoring as a way to profile gene expression 
in relation to human environmental exposures.    
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The EU research project found that gene expression profiles differed 
according to the population’s environmental exposure.  This finding resulted 
in the correlation between gene expression and the blood/urinary measures of 
biomarkers used to observe environmental carcinogen exposure.  The EU 
project also provided evidence that exposure to environmental carcinogens 
affected the metabolism, stress response, signaling pathway, and the 
tumorigenesis of the studied genes.  Overall, the EU is pressing for an 
increase in biomonitoring activities during the analysis of environmental 
health risks (Van Leeuwen et al., 2008).   
According to Adelman (2005) the United States employs inadequate 
chemical testing methods to determine chemical risk.  Both chemical risk 
assessments and toxicological studies face limitations due to the lack of 
chemical information.  As a method to combat these limitations, the 
integration of genomics and toxicology is developing into a new research field 
call toxicogenomics.  Toxicogenomics will help to identify biomarkers of 
exposure as well as relate disease to an environmental exposure.  To promote 
the technological development to monitor gene, protein, and metabolite 
expression, the National Institute of Environment Health Science (NIEHS) has 
developed the National Center for Toxicogenomics.  As of 2002, the Center 
was awaiting a tool to monitor the expression of thousands of genes, proteins, 
metabolites, and gene-environment interactions (Tennant, 2002).  
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iv. Chemical Properties  
A method of assessing chemicals is through structure-activity relationships 
(SARs).  SARs are designed to find the relationship between chemical 
structure, chemical structure related properties, and biological activity 
(OECD, 2016).  SARs link chemical structure to a chemical property or a 
biological activity such as toxicity (OECD, 2016).   According to the 
Organization for Economic Co-operation and Development (OECD) (2016), 
the theory behind SARs is that the activity of the chemical is found within the 
chemical’s structure.  Therefore, the structure of a chemical contains the 
features responsible for the chemical’s physical, chemical, and biological 
properties (OECD, 2016).  The biological activity of a compound may alter 
the chemical or physiological function of a cell, tissue, organ, or organism 
through the compound’s physical and chemical makeup, concentration, and 
duration of exposure.  OECD (2016) presumes that biological activities of a 
compound are governed by the compound’s properties, which are determined 
by the compound’s structure.   
Abraham et al. (1989) considered the molecular weight and number of 
hydrogen bond donors and acceptors as physicochemical properties. 
Physicochemical properties predict a chemical’s physical hazard, reactivity, 
and pharmacokinetics to include the chemical’s absorption through exposure 
routes, the chemical’s distribution in the body, and the chemical’s metabolites.  
By understanding a chemical’s pharmacokinetics and physicochemical 
properties, Abraham et al. (1989) identified the key properties responsible for 
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chemical absorbtion through various exposure routes.  Molecular weight, the 
number of hydrogen-bond donors and acceptors, and logKow were identified as 
predictors of oral absorption.  Chemical absorption through the skin depended 
upon the degree of hydrogen bonding.  Unlike ingestion and cutaneous 
absorption, chemical inhalation prediction requires the use of vapor pressure, 
water solubility, and the chemical’s reactivity.  
Understanding the chemical characteristics that affect toxicity, Abraham et 
al. (1989) determined that a chemical with a large number of hydrogen bond 
donors had a reduced permeability rate.  Chemicals with five or fewer 
hydrogen bond donors had an increase in permeability.  When studying the 
molecular weight, Abraham et al. (1989) determined that lower molecular 
weight compounds maintained a lower lipophilicity, while higher molecular 
compounds resulted in higher lipophilicity.  As a result of this study, Abraham 
et al. (1989) determined that higher molecular weight chemicals resulted in 
reduced blood brain barrier permeability (Abraham et al., 1989).     
Furthering the Abraham et al. (1989) study, Lipinski et al. (1997) analyzed 
the physiochemical properties of 2,000-plus drugs to determine drug 
permeability and absorption potential.  During their analysis, Lipinski et al. 
(1997) determined that permeability rates and absorption potential increased 
due to a compound’s molecular weight, lipophilicity (expressed as logP), 
number of hydrogen bond donors, and the number of hydrogen bond 
acceptors.  The Lipinski et al. (1997) findings are known as the Lipinski Rule 
of Five; which determines a compound’s membrane permeability and ease of 
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absorption when the compound has a molecular weight less than 500, a 
lipophilicity less than five, the number of hydrogen-bond donors is fewer than 
five, and the number of hydrogen-bond acceptors is fewer than 10.  
Using known toxic compounds, Struck et al. (2008) determined the 
biological activity toxicity profile for 50,000 toxic compounds for use as a 
toxicological classification guide.  Struck et al. (2008), identified toxic 
compounds based on their structural properties.  The structural properties 
identified as “toxicity properties” contain toxicity defining attributes identified 
as the compound’s molecular weight, the number of hydrogen bond donors 
and acceptors, and functional groups (Struck et al., 2008).  Struck et al. 2008 
identified that the use of SARs for predicting toxicity is limited due to the 
complexity of the structure of toxic biological macromolecules, the variability 
of metabolic pathways, toxicity differences among animal and plant species, 
the effects of substituents on the reactivity of the core chemical, and the effect 
of steric properties.  However, some researchers have developed SARs based 
on key structure components.  
b. Burn pits  
i. Burn Pit Emissions: 
Due to the limited nature of open air burn pit emission studies, and the 
difficulty of assessing, characterizing, and quantifying burn pit emissions and 
associated exposures, Lemiux et al. (2004) identified that emissions from 
burning waste varied from source to source.  Lemiux et al. (2004) identified 
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that the fuel composition, fuel heating value, bulk density, oxygen transport, 
and combustion varied from source to source.  
Woodall et al. (2012) attempted to characterize burn pit emissions during 
small-scale emissions testing of simulated military deployment waste. 
Woodall et al. (2012) identified burn pit constituents using a representative 
collection of military waste based on expert knowledge of DOD personnel.  
The waste stream sampled consisted of large amounts of styrofoam, 
electronics, packaging materials, construction materials, food waste, canvas 
material, Meals Ready to Eat (MRE) waste, and plastic water bottles.  The 
analysis of the emissions testing concluded that 47 volatile organic 
compounds (VOCs) were present in the burn pit emissions.  Ten of the 47 
VOCs lacked constructed curated chemical-disease relationships by the CTD, 
thus becoming the uncurated chemical constituents tested within this thesis.  
Aurell et al. (2012), further characterized burn pit emissions to assess 
potential inhalational exposures.  Aurell et al. (2012) collected 41 Semi-VOCs 
(SVOCs), PM2.5 by filter, and VOC samples.  21 VOCs were found to be 
present in the Aurell et al. (2012) burn pit emissions.  Three of the 21 VOCs 
lacked constructed chemical-disease relationships by the CTD.  The Woodall 
et al. (2012) and the Aurell et al. (2012) study found two of the same 
uncurated constituents: propene and vinyl acetate.  15 of the 21 VOCs 
identified in the Aurell et al. (2012) study are listed as EPA hazardous air 
pollutants.  The Aurell et al. (2012) study also identified the following 
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emissions: phenanthrene, naphthalene, lead, iron, copper, chromium, arsenic, 
nickel, and cadmium. 
ii. The Relationship between Uncurated Burn Pit Constituents and Disease 
The following research was accomplished to identify the relationship 
between the ten uncurated burn pit constituents identified by Woodall et al. 
(2012) and their known disease associations.  In order to understand the 
relationship between uncurated constituent and disease, the mechanism or 
mode of action was also identified for each uncurated chemical.  The 
qualitative impacts of the associated diseases, mechanisms and modes of 
action are not fully defined and exclude the quantitative differences between 
test species.  Additionally, the mechanism or modes of action that cause 
disease are not considered a constant property of the chemical.  The 
mechanism or mode of action that causes disease are subject to variation 
between species and may change with chemical concentration and duration of 
exposure (Nendza and Wenzel, 2006).   
The physio-chemical properties of chemical compounds are toxic in 
different ways due to the compound’s interactions at the biomolecular level.  
Nendza and Wenzel (2006) identified that physio-chemical properties also 
determine the transport and interaction of the compound with biomolecular 
targets.  Partitioning of the chemical across a membrane often resulted in non-
specific toxicity, while chemical interaction between compounds with specific 
targets produced an increase in toxicity (Nendza and Wenzel, 2006).  Nendza 
and Wenzel (2006) also determined that chemical compounds did not 
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maintain the same mechanism of action during cross species analysis.  The 
change in the mechanism of action across species was determined to occur 
from the change in the abundance of mechanism specific targets and the 
endpoint measured by each experiment.   
Chemical compounds are also hypothesized to interact with several targets 
to varying extents in different species.  These interactions between the 
chemical and the varying targets may result in multiple concurrent effects.  
20% of the chemicals tested by Nendza and Wenzel (2006) demonstrated two 
concurrent mechanisms of disease, and 5% of the chemicals tested revealed 
three concurrent mechanisms of disease.    
The following diseases, mechanisms or modes of action for the ten 
uncurated burn bit constituents are based on the best available research.  The 
MoA/MOA for each constituent was selected using metabolism and 
pharmacokinetic studies. 
1. 4-Ethyltoluene 
4-Ethyltoluene is an active sister chromatid exchange agent in vitro 
balb mice bone marrow cells (Janik-Spiechowicz and Wyszynska (1998).  
Sister chromatid exchanges (SCEs) involve the breakage of both DNA 
strands, followed by an exchange of the whole DNA strand.  SCEs have 
been correlated with recombinational repair and the induction of point 
mutations, gene amplification and cytotoxicity (CRIOS, 2008).  According 
to the National Library of Medicine (2013), point mutations are associated 
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with the development of cystic fibrosis.  The Cancer.Net Editorial Board 
(2012) found that point mutations have been associated with cancer.   
Swiercz et al. (2000) found that in vivo rat repeated-dose inhalational 
toxicity studies to 4-ethyltoluene resulted in elevated serum levels of 
gamma-glutamyl transferase (GGT); a biomarker of oxidative stress.  
Oxidative stress may damage cells by damaging proteins, lipids, and DNA 
which can disrupt the cellular signaling mechanisms.  Slupphaug et al. 
(2007) identified DNA Damage caused by oxidative stress may prevent 
proper base pairing resulting in strand breaks.  In humans, oxidative stress 
is hypothesized to be involved in the development of neurodegenerative 
diseases (Patel and Chu, 2011), cancer (Halliwell, 2007), atherosclerosis 
(Bonomini et al., 2008), heart failure (Singh et al., 1995) myocardial 
infarction (Ramond et al., 2011), and chronic fatigue syndrome (Kennedy 
et al., 2005).   
Swiercz et al. (2000) also identified the concentration-related increase 
in lactate dehydrogenase (LDH) with in vivo rat repeated-dose 
inhalational toxicty studies to 4-ethyltoluene.  LDH is medically 
significant due to its release when tissue damage has occurred.  As a 
biomarker of oxidative stress, LDH is a commonly linked to heart failure, 
liver disease, cancer (Gersten, 2014), lung disease (Drent et al., 1996), and 
hypothyroidism (McGrowder et al., 2011).  Yorifuji et al. (2012) identified 
a prevalence of respiratory and mucocutaneous zone irritation when 
          
25 
exposed to VOCs containing 4-ethyltoluene.  4-Ethyltoluene mechanisms 
stated above are consistent with the irritant properties of VOCs.    
2. Benzanthrone 
Singh et al. (2003) discovered that benzanthrone could induce lipid 
peroxidation in vivo guinea pig comparative safety assessments.  Lipid 
peroxidation is one of the main molecular mechanisms involved in the 
oxidative damage to cellular structures and the toxicity process that leads 
to cellular death (Repetto et al., 2012).  According to TOXNET (2003), 
benzanthrone induced toxicity is suggested to take place in areas of the 
cell where there is an increase in the production of lipid peroxides.  These 
areas include the nuclear, mitochondrial, and microsomal membranes.  
Further evaluations revealed enhanced oxidative stress, upregulation of 
prominent inflammatory markers, and DNA damage coinciding with 
benzanthrone exposures.  Tewari et al. (2015) found that the 
administration of benzanthrone in vivo studies with mice also induced 
enzyme activation that consisted of mechanistic pathways involved in 
inflammatory manifestations, which suggests that benzanthrone is an 
immunotoxin agent.  Upon exposure to light benzanthrone generates 
active oxygen species.  The National Research Council (1999) 
hypothesized that the active oxygen generation of benzanthrone might be 
responsible for the photo-contact dermatitis experienced in humans.  The 
oxidative stress mechanism associated with benzanthrone is consistent 
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with the skin disorders documented with contact exposures to 
benzanthrone.     
Sidhu et al. (2005) identified benzanthrone as a suspected human 
Endocrine disrupting chemical (EDC) based on the structual similarities to 
both known and suspected EDCs.  De Coster and Van Larebeke (2012) 
discerned that EDCs mimic or block the transcriptional activation elicited 
by naturally circulating steroid hormones by binding to steroid hormone 
receptors.  EDCs increase or block the metabolism of naturally occurring 
hormones by activating or antagonizing estrogen, androgen, and thyroid 
hormone receptors.  Tabb and Blumber (2013) observed EDCs effect on 
the genome, DNA, and lipid metabolism.   
3. Benzyl Chloride  
Evaluation of benzyl chloride by TOXNET (2014) identified benzyl 
chloride as causing an increase in the alkylation of DNA resulting in 
alkylation lesions in DNA and RNA in vivo mice studies.  Drabløs et al. 
(2004) demonstrated how alkylation lesions may result in genotoxicity and 
cytotoxicity, eventually resulting in cytotoxic double-strand breaks of the 
DNA.  Alkylating agents, like benzyl chloride, inhibit the transcription of 
DNA into RNA, thus stopping protein synthesis, which triggers 
apoptosis.  Alkylating agents also substitute alkyl groups for hydrogen 
atoms in the DNA sequence, resulting in the formation of cross-links in 
the DNA chain.  The National Library of Medicine (NLM) (2015) 
identified that cross links in the DNA sequence can result in cytotoxic, 
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mutagenic, and carcinogenic effects.  Typically, alkylating agents 
primarily affect hematopoietic cells, reproductive cells, endothelial cells, 
bone marrow, and the cells of the gastrointestinal tract.  The NLM (2015) 
also associated the common side effects of alkylating agents.  These side 
effects include anemia, pancytopenia, amenorrhea, impaired 
spermatogenesis, intestinal mucosal damage, alopecia, and an increased 
risk of malignancy.  Benzyl Chloride animal carcinogenicity is consistent 
with the alkylation of DNA mechanisms.   
Similar to benzanthrone, benzyl chloride also induces lipid 
peroxidation during in vitro rat liver testing (EC, 2014).  Benzyl chloride 
also produced SCE with point mutations in vitro hamster studies (EC, 
2014).  Disparate from the other uncurated burn pit chemicals, benzyl 
chloride is associated with a dose-dependent increase in the number of 
chromatid aberrations in rat epithelial cells (EU, 2014).  The chromatid 
aberrations created by benzyl chloride produce breaks and gaps in the 
chromatids during and after replication.  Chromatid aberrations often 
result in chromosomal or genome mutations.   
Benzanthrone is a Polycyclic Aromatic Hydrocarbon (PAH).  Abdel-
Shafy and Mansour (2015) describe PAHs as highly lipid soluble in 
mammalian gastrointestional tracts.  Abdel-Shafy and Mansour (2015) 
further describe both acute and chronic effects of PAH exposure with the 
caveat that short-term human health effect information of PAHs is not 
clear.  High levels of PAH exposures have resulted in eye irritation, 
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nausea, vomiting, diarrhea, and confusion in humans (Abdel-Shafy and 
Mansour, 2015).  Long-term human exposures to PAHs have resulted in 
decreased immune function, cataracts, kidney damage, liver damage, 
breathing problems, asthma-like symptoms, lung function abnormalities, 
skin redness, and skin inflammation (Abdel-Shafy and Mansour, 2015). 
Irigaray and Belpomme (2009) suggest that PAHs with low molecular 
weights and three to four rings are non-genotoxic carcinogen promoters 
causing the expansion of initiated cells.  Non-genotoxic promoters are also 
suggested to cause preneoplastic cells to escape cellular growth control 
mechanisms.  Irigaray and Belpomme (2009) also suggest that PAHs are 
cocarcinogens, whereas, cocarcinogens activate carcinogens, and may 
enhance the carcinogens effects.  The mechanisms by which 
cocarcinogens activate, enhance, or effect carcinogens are through the 
depletion of detoxifying proteins, inhibit enzymatic activity, inhibit DNA 
repair enzymes, and/or activate procarcinogenic material into carcinogenic 
material.  
4. n-Heptane 
The irritation and central nervous effects occurring from n-heptane 
exposures are linked to the lipophilic properties of n-heptane (MAK Value 
Documentation, 1998).  Szutowski (2009) suggests that cytochrome P450 
produces n-heptane metabolites which modulate the biotransformation of 
n-heptane, resulting in the oxidation of n-heptane during in vitro rat 
studies.  Oxidation in the body can damage cell membranes, cellular 
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proteins, lipids, and DNA.  Oxidative DNA damage may result in the 
production of single or double stranded DNA breaks, base modifications, 
or rearrangements.  Due to the limited research available, n-heptane’s 
mechanisms of disease could not be compared to n-heptane 
symptomology.  
5. n-Octane 
Similar to n-heptane, n-octane is also metabolized by cytochrome 
P450 and undergoes oxidation.  An in vivo rat study by Pandya et al. 
(1982) cited in TOXNET (2014) observed the increase in liver and spleen 
alkaline phosphatase (ALP) when exposed to n-octane.  Increased ALP 
activity is associated with hepatobiliary and bone diseases.  Tietz (1999) 
associated elevated ALP levels with disorders of the skeletal system, 
hyperparathyroidism, osteomalacia, fractures, and malignant tumors.  
Khan et al. (1980) linked n-octane to lipid peroxidation induction.  
Yorifuji et al. (2012) identified a prevalence of respiratory and 
mucocutaneous zone irritation when exposed to VOCs containing n-
octane.  n-Octane mechanisms stated above are not consistent with the 
irritant properties of VOCs.    
6. Propene 
Propene is expected to undergo hydration becoming an alcohol, and is 
later excreted as a conjugated alcohol or propionic acid.  Similar 
hydroxylate chemical reactions involve cytochrome P450.  TOXNET 
(2005) hypothesizes that propene may be metabolized by cytochrome 
          
30 
P450.  Due to the limited research available, propene’s mechanisms of 
disease could not be compared to propene symptomology. 
7. Salicylaldehyde 
Freda (1970) demonstrated salicylaldehyde’s enzyme inhibition effects  
in vitro bovine testing.  Enzyme inhibitors alter the catalytic action of 
enzymes causing a delay or discontinuance of catalysis.  Similar to 
benzanthrone, the EPA classified salicylaldehyde as an EDC.  De Coster 
and Van Larebeke (2012) suggest that EDCs contribute to cancer, 
diabetes, obesity, metabolic syndrome, and infertility.  EDCs may act 
through classical nuclear receptors, but also through estrogen-related 
receptors, resulting in enzyme activation or modulation.  De Coster and 
Van Larebeke (2012) proposed that EDCs interfere with feedback 
regulation, neuroendocrine cells, DNA methylation, which results in 
histone modifications, while Tabb and Blumber (2013) suggests that 
EDCs activate mitogen-activated protein kinase.  Due to the limited 
research available, salicylaldehyde’s mechanisms of disease could not be 
compared to salicylaldehyde symptomology. 
8. Tetrahydrofuran 
The mode of action and the biotransformation mechanisms of 
Tetrahydrofuran (THF) are not well understood.  The Proposal for 
Harmonised Classification and Labeling (2009) hypothesized that 
tetrahydrofuran undergoes an alpha-hydroxylation, followed by a 
subsequent ring opening.  This process is suspected to produce a 
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hepatotoxic aldehyde.  The Proposal for Harmonised Classification and 
Labeling (2009) also hypothesized that the oxidation of the hydroxyl 
group before the ring opening occurs, leading to the formation of a 
gamma-butyrolactone; a potential neurotoxic and a gamma-hydroxibutyric 
acid.     
The European Chemical Agency (ECHA) (2010) suggests that 
tetrahydrofuran is capable of inhibiting cytochrome P450 in vitro rat 
biotransformation studies.  This inhibition of cytochrome P450 may cause 
the formation of peroxides and formaldehyde to occur.  The Proposal for 
Harmonised Classification and Labeling and ECHA also suggest that 
tetrahydrofuran oxidative metabolism occurs due to cytochrome P450.  
However, the enzymes responsible for Tetrahydrofuran metabolism are 
not yet known.  
Mode of Action in vivo rat research conducted by ECHA suggests that 
the tetrahydrofuran is responsible for liver toxicity while the metabolites 
of tetrahydrofuran are responsible for neurological effects.  In vivo 
tetrahydrofuran studies also produced mitogenic effects in mice tissue, yet 
tetrahydrofuran demonstrated the ability to modify drug absorption and 
metabolism mechanisms, which may give rise to chemical distinctive 
toxicities.   
Chhabra et al. (1998), and the U.S. Department of Health and Human 
Services (1998) as cited in TOXNET (2011), identified tetrahydrofuran as 
an animal carcinogen during in vivo rat and mouse inhalational studies.   
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Tetrahydrofuran demonstrated positive results for liver 
adenoma/carcinoma, and renal tubule adenoma/carcinoma, in both rat and 
mouse test subjects.  These studies indicate that the oxidative stress and 
the metabolism of tetrahydrofuran are realistic mechanisms of disease for 
tetrahydrofuran exposures.   
9. Triphenylene 
Triphenylene is a Polycyclic Aromatic Hydrocarbon (PAH).  
Historically, the toxic effects of highly lipid soluble polycyclic aromatic 
hydrocarbons were not well documented (Sikkema et al., 1995).  
However, Sikkem et al. (1995) concluded that the specific toxicity of 
certain PAHs, when performed with a liposomal model, show that the 
absence of mass transfer limitation affects the PAHs energy transduction 
across biological membranes. 
Irigaray and Belpomme (2009) suggest that PAHs with low molecular 
weights and three to four rings are non-genotoxic carcinogen promoters 
causing the expansion of initiated cells.  Non-genotoxic promoters are also 
suggested to cause preneoplastic cells to escape cellular growth control 
mechanisms.  Irigaray and Belpomme (2009) also suggest that PAHs are 
cocarcinogens, whereas, cocarcinogens activate carcinogens, and may 
enhance the carcinogens effects.  The mechanisms by which 
cocarcinogens activate, enhance, or effect carcinogens are through the 
depletion of detoxifying proteins, inhibit enzymatic activity, inhibit DNA 
repair enzymes, and/or activate procarcinogenic material into carcinogenic 
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material.  Due to the limited research available, triphenylene’s 
mechanisms of disease could not be compared to triphenylene 
symptomology. 
10. Vinyl Acetate 
Similar to 4-ethyltoluene, vinyl acetate also induces SCE in 
mammalian in vitro studies.  Unlike 4-ethyltoluene, vinyl acetate induced 
structural chromosome aberrations which further induce DNA cross-links 
mammalian in vitro studies.  The Proposal for Harmonised Classification 
and Labeling (2010) identified that vinyl acetate induced changes causing 
fatty degeneration of hepatic parenchyma, and the proliferation and 
extension of smooth endoplasmic reticulum.  Vinyl acetate also caused 
cell proliferation, cytotoxic effects, and mitotic inhibition during in vivo 
rat studies.  Acetaldehyde, a metabolite of vinyl acetate through esterase-
mediated metabolism, exhibited genotoxicity, induced DNA protein 
crosslinking and chromosomal damage in mammalian in vitro testing.     
A risk assessment accomplished for the European Commission (EC) 
(2008) on vinyl acetate, identified vinyl acetate as genotoxic having a 
threshold mode of carcinogenic action in vivo rat studies.  Genotoxic 
carcinogens damage DNA through covalently binding to the DNA.  The 
DNA binding can occur as a direct binding to the DNA, after enzymatic 
activation, or by insertion into the DNA double helix (Van Delft et al., 
2004).  DNA damage can result in the dysfunction of the cell cycle, DNA 
repair, and lead to apoptosis. 
          
34 
The 2008 European Commission Risk Assessment identified vinyl 
acetate as inducing cellular proliferation at high levels during cancer 
studies.  During the cancer studies, EC researchers assumed that 
cytotoxicity was the underlying mode of carcinogenesis.  In vivo rat 
studies vinyl acetate exposures resulted in an increase in cell proliferation 
due to mitogenic actions, which lead to tumor formation.  The European 
Commission (2008) presently accepts that acetaldehyde plays a critical 
role in the tumorigenicity of vinyl acetate, and suggests that the hydrolysis 
product of acetaldehyde is the active carcinogenic metabolite of vinyl 
acetate.  Vinyl acetate symptomology is consistent with the established 
mechanisms of disease. 
c. Using ANNs for predictive modeling 
An artificial neural network (ANN) is a computational empirical model that is 
modeled after biological neurons.  ANNs consist of inputs, weights, and 
mathematical functions in order to detect complex nonlinear relationships 
between dependent and independent variables in a given data set.  Adjusting the 
weight of an ANN symbolizes how the model can be trained in order to obtain an 
output for a set of given inputs.  Since the first use of ANNs in 1943 (Gershenson, 
2016), ANNs have been used to map associations when the data contains 
variables that are vague, or difficult to describe.  ANNs are currently used in 
diagnostic systems, biochemical analysis, image analysis, and drug development.  
The pharmaceutical industry is using ANNs to associate subsets of 
physiochemical descriptors with biological activity profiles to provide an 
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understanding of how biological activity is elicited by a chemical structure.  
Llewellyn (2007) used this approach to predict drug likeness and toxicological 
effects.  Unlike the pharmaceutical industry, the medical industry according to 
Rae et al. (1999) applied the use of ANNs as a decision support tool to help 
clinicians identify populations who are at an increased risk for developing specific 
diseases.  The medical use of ANNs demands extensive development into the type 
and number of parameters used by the ANN—specifically the number of neurons 
in each layer and the applied learning algorithm.  
Other medical uses of ANNs have occurred when Sheppard et al. (1999) used 
neural networks to identify potential patients at risk of developing 
cytomegalovirus disease.  Santos-Garcia et al. (2004) also used ANNs to predict 
patients’ morbidity from cardiorespiratory failure after non-small cell lung cancer 
pulmonary resection.  Tseng et al. (2013) examined patient risk factors associated 
with hip fractures using ANNs.  Alizadeh et al. (2015) created an ANN that 
accurately predicted the diagnosis of asthma.      
d. Using ANNs to link chemicals and disease 
ANNs have established their usefulness in medical and pharmaceutical 
prediction.  However, research is limited to demonstrate how ANNs model 
chemical-disease association.  Most often the research on the prediction of 
chemical-disease association involves the use of ANN Quantitative Structure 
Toxicity Relationship (QSTR) and an ANN Quantitative Structure-Activity 
Relationship (QSAR).  ANN QSTRs are often used to map the relationship 
between a chemical’s molecular descriptors and its toxicological activity, while 
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QSARs correlate physiochemical parameters to either a chemical or biological 
activity.  Cheng and Sutariya (2012) describe the use of ANN QSTR in the study 
of pharmacotoxicology, and the use ANN QSAR as a screening approach during 
the drug discovery process.  
Modeling drug response, Larder et al. (2007) demonstrated the use of an ANN 
developed to predict responses to antiretroviral therapy.  Larder et al. (2007) 
identified that their developed ANN is limited by its capacity to only predict 
response to drugs that are included in the training dataset; thus, creating the need 
for further training of their model.  Sibanda and Pretorius (2012) detailed the use 
of ANNs in the war against the Human Immunodeficiency Virus (HIV).  As cited 
by Sibanda and Pretorius (2012), Dechao Wang et al. (2009) developed an 
artificial neural network (ANN) that predicted the virological response to HIV 
drug therapy.  Similarly, Agatonovic-Kustrin and Beresford (1999) showed that 
their ANN model demonstrated better fitting and better predicting abilities in their 
investigation of the effects of pharmaceuticals.  The ANN developed by 
Agatonovic-Kustrin and Beresford (1999) produced correlation values indicating 
strong association between the testing and training data.  The high correlation 
values demonstrated that the ANN was able to predict pharmacokinetic and 
pharmacodynamic (PK-PD) relationships.  
In the attempt to understand compound specific toxicity, Vracko et al. (1999) 
demonstrated the difficulty of using ANNs to predict toxic effects.  Vracko et al. 
(1999) displayed the complications of predicting specific toxicities for 41 benzene 
analogues.  However, the Vracko et al. (1999) ANN established that ANNs were 
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better capable of predicting toxicity classes versus predicting compound specific 
toxicity.  Villemin et al. (1994) used an ANN to predict the carcinogenicity of 94 
PAHs.  The Villemin et al. (1994) ANN correctly associated and classified 81 of 
the 94 PAHs according to their activity.  Gini et al. (1999) identified that 
molecules with identical or similar chemical descriptors differ in toxicity.  The 
toxicity difference occurred due to the diversity in test animal metabolism.  The 
ANN used by Gini et al. (1999) was not able to distinguish the toxicity between 
certain chemicals with similar descriptors, resulting in the need for further 
knowledge of the bioprocesses involved in chemical metabolism and the 
structural features of the chemical that characterize the chemical’s specific 
mechanism of action.  
2. Summary 
The articles reviewed and discussed in the above literature review represent a 
small research sample related to the key concepts used to develop this thesis.  The 
purpose of this literature review was intended to provide a general familiarization 
with current and relevant research regarding chemical-disease relationships, burn pits, 
and artificial neural networks.  As a result of current and relevant research, the use of 
ANNs as predictors of disease have been used and verified in various capacities.  
However, the DOD as an aid in predictive applications has not employed the use of 
ANNs.  Identifying burn pit constituents, their physicochemical properties, their 
anticipated acute health effects, and chronic health risks can be characterized using an 
ANN.  Existing data gaps between chemical relationships, biomarkers, and disease 
will be identified with the expectation that further research will occur.  While the goal 
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of the analysis was to provide a decision-support tool, the risk-assessment related 
burn pit exposures would aid in the anticipation, recognition, prevention, mitigation, 
control, communication, and documentation of future exposures. 
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III. Methodology 
1. Data 
a. Training Data 
The data used to train the Brouch MATLAB® ANN was obtained and used 
previously by Brouch (2014).  Training input data was originally obtained from 
curated Comparative Toxicogenomics Database (CTD) data.  The chemicals used 
in the Brouch MATLAB® ANN were selected randomly from curated CTD data 
by Brouch (2014).   
b. Testing Data  
The data used to test the Brouch MATLAB® ANN was obtained from 
Woodall’s (2012) burn pit constituent air sampling and thesis.  Woodall (2012) 
identified 47 VOCs in the burn pit air sampling results.  Each VOC was 
selectively compared to curated CTD data to verify the constituent’s curation 
status.  Ten of the 47 VOCs were not curated by the CTD.  The ten VOCs were 
then curated by the author to identify the following: chemical structure, molecular 
weight, the number of hydrogen bond acceptors, the number of hydrogen bond 
donors, mechanism/mode of action, and related associated diseases. 
c. Constituents 
Table 1 displays the selected ten uncurated constituents.  Table 1 lists the 
constituent name, synonyms, chemical abstracts service (CAS) number, molecular 
weight, structure diagram, associated diseases, and associated mechanism/mode 
of action.  Chemical-associated diseases were selected based on toxicity studies 
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using only the specified chemical and no chemical mixtures from peer-reviewed 
literature.  
i. 4-Ethyltoluene 
4-Ethyltoluene is a benzene derivative.  At this time, research is limited on 
4-ethyltoluene and its effects (PubChem, 2015).  A study performed by 
Yorifuji et al. (2012) identified 4-ethyltoluene as a VOC constituent being 
released from a plastic reprocessing factory in Japan.  Based on the study 
performed by Yorifuji et al. (2012), the researchers found a prevalence of 
mucocutaneous and respiratory symptoms in residents closest to the plastics 
factory.  Other symptoms experienced during this study include sore throat, 
eye itch, eye discharge, eczema, and sputum (Yorifuji et al., 2012). 
ii. Benzanthrone 
Benzanthrone is an industrial chemical that can be found in dye 
intermediates and as a product of fossil fuel combustion (TOXNET, 2003).  
Benzanthrone has been detected in particulates from diesel engines’ exhaust, 
municipal waste incinerator ash, and wood and coal smoke.  Due to the vapor 
pressure of benzanthrone, it will exist in both the vapor and particulate phases 
in the atmosphere.  Exposure to benzanthrone can occur through dermal 
contact, inhalation, and ingestion.  Skin disorders due to benzanthrone are 
more frequent in warm seasons and are significantly aggravated by heat and 
light (Encylopedia of Occupational Health and Safety, 1971)  
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Chronic exposures to benzanthrone have been documented to cause loss of 
appetite resulting in weight loss, intolerance of fatty foods, liver impairment, 
and gastritis.  Workers reported general fatigue and weakness along with 
complaints of decreased sexual potency, increased neurasthenic syndrome, 
accelerated pulse, and reduced blood pressure.  Contact exposures to 
benzanthrone have resulted in skin sensitization, eczema, erythema, 
dermatitis, and skin pigmentation.  A study performed by Sidhu et al. (2005), 
identified benzanthrone as a suspected Endocrine Disrupting Chemical 
(EDC).  
iii. Benzyl Chloride 
Benzyl chloride is used as a chemical intermediate in the manufacture of 
dyes, pharmaceutical products, photographic developer, perfume, flavor 
products, synthetic tannins, pesticides, and petrol (TOXNET, 2015).  Acute 
occupational exposures to benzyl chloride have resulted in respiratory tract, 
skin, eye, pulmonary, and mucous membrane irritation.  Other 
symptomatology includes severe irritation of the upper respiratory tract with 
coughing, conjunctivitis, dizziness, weakness, headache, eyelid and finger 
tremors, increased bilirubin levels in blood, and a decrease in number of 
leukocytes.  Lung damage, pulmonary edema, permanent eye damage, and 
CNS depression are suspected after severe benzyl chloride exposure 
(TOXNET, 2015).   
Animal data indicate that long-term exposure to benzyl chloride showed 
an increase in the incidence of benign and malignant tumors, along with an 
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increase in thyroid tumors in female rats.  At this time, there is limited human 
evidence for the carcinogenicity of benzyl chloride.  Based on the coupling of 
animal studies and the insufficient and inadequate data on human studies, the 
EPA (2000) has classified benzyl chloride as a Group B2, probable human 
carcinogen.  American Conference of Governmental Industrial Hygienists 
(ACGIH) classified benzyl chloride as a confirmed animal carcinogen with 
unknown relevance to humans (HSDB, 2015)  
The EPA (2000) detected benzyl chloride in air emissions from the 
burning of polyvinyl chloride, neoprene, and urethane foam compounds.  The 
EPA (2000) reported acute exposure to high concentrations of benzyl chloride 
causing central nervous system impairment including dizziness, headaches, 
weakness, and fatigue.  Eye contact with benzyl chloride may result in 
permanent eye damage, while ingestion of benzyl chloride may cause mouth, 
throat, and gastro-intestinal tract burns that result in nausea, vomiting, cramps, 
and diarrhea (EPA, 2000).   
The chronic effect of benzyl chloride exposure in humans has not been 
studied.  However, chronic animal exposure to benzyl chloride suggests that 
benzyl chloride specifically targets the stomach and heart.  At this time, there 
are no studies indicating human developmental or human reproductive effects.   
However, a rat in vivo study demonstrated an increase in embryonal mortality, 
along with developmental retardation in the offspring of exposed rats.  
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iv. n-Heptane 
n-Heptane is used as an industrial solvent, anesthetic, laboratory reagent, 
in the petroleum refining process, and as a paint/coating additive (NJ DOH, 
2007).  Consumer use of n-heptane includes adhesives, sealants, automotive 
care products, ink, toner, and plastic/rubber products (PubChem, 2015).  
Acute exposure to n-heptane has been documented to cause eye, nose, and 
throat irritation, headache, lightheadedness, dizziness, lack of coordination, 
loss of consciousness, and loss of appetite.  Chronic exposure to n-Heptane 
included skin rash, skin dryness, and skin redness.  Limited research suggests 
that n-heptane may affect the central nervous system to include symptoms of 
memory loss, withdrawal, irritability, fatigue, sleep disturbances, and 
extremity weakness.  Historically, the EPA (1989) did not classify n-heptane 
as a carcinogen and could not verify n-Heptane’s ability to cause reproductive 
hazards.   
v. n-Octane 
n-Octane is used as a fuel additive, paint/coating additive and as a solvent 
(HSDB, 2014).  A study performed by Yorifuji et al. (2012), identified n-
octane as a VOC constituent being released from a plastic reprocessing 
factory in Japan.  Based on the study performed by Yorifuji et al. (2012) a 
prevalence of mucocutaneous and respiratory symptoms in residents closest to 
the plastics factory was found and associated with n-octane exposures.  
Specifically, the symptoms of sore throat, eye itch, eye discharge, eczema, and 
sputum were increased among the residents (Yorifuji et al., 2012).  Human 
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exposure studies to n-octane, have determined that n-octane exposure can 
cause giddiness, vertigo, headaches, stupor, epileptic seizures, respiratory tract 
irritation, visceral damage, chemical pneumonitis, pulmonary edema, skin 
blisters, and hemorrhaging (HSDB, 2014).    
vi. Propene 
Propene is used in plastics, carpet fibers, as a fuel additive, chemical 
intermediate, aerosol propellant, and in medication (HSDB, 2014).  Acute 
exposures to propene have been documented to cause dizziness, 
lightheadedness, and loss of consciousness.  Chronic exposures to propene 
include liver damage and irregular heart-beat.  At this time, there is inadequate 
evidence and testing establishing propene’s carcinogenicity.  Propene has not 
been tested to verify reproductive hazards (NJ DOH, 2004).     
vii. Salicylaldehyde  
Salicylaldehyde is a chemical reagent and can be found in perfumes, 
fumigants, gasoline, flavor ingredients, and in medicinal chemicals (HSDB, 
2003).  A study performed by Sidhu et al. (2005) identified salicylaldehyde as 
a suspected Endocrine Disrupting Chemical (EDC).  The EPA (2015) also 
considers salicylaldehyde an EDC.   
viii. Tetrahydrofuran 
Tetrahydrofuran is used as a reaction medium, reagent, and solvent in 
various operations that involve printing inks, adhesives, lacquers, coatings, 
fuels, pharmaceuticals, perfumes, insecticides, resins, vinyl, polymers, and 
cellophane.  Data on Tetrahydrofuran toxicity is limited.  TOXNET (2015) 
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identified several animal studies that correlated tetrahydrofuran exposure to 
skin and mucous membrane irritation, respiratory tract irritation, liver damage, 
kidney damage, lung damage, and gastro-intestinal tract inflammation.  
Similar to benzyl chloride, the ACGIH also confirmed tetrahydrofuran as an 
animal carcinogen with unknown relevance to humans (HSDB, 2015).       
ix. Triphenylene 
Triphenylene research and studies are rare in nature.  Two mutagenicity 
studies were located and examined for relevance.  Both studies identified 
triphenylene as causing mutagenicity with positive results in the AMES tests 
with and without S9 fraction from rat livers (CCRIS, 1985).  The AMES test 
is used to determine if a chemical can induce mutations in DNA—thus 
establishing a chemical’s mutagenicity (DeStasio, 2015). 
x. Vinyl Acetate  
Vinyl acetate is used in plastics, films, lacquers, food packaging, food 
starches, polyvinyl emulsions, resins, coatings, paints, sealants, construction 
products, carpet backing, chewing gum, tablet coatings, acrylic fibers, air 
sprays, textiles, paper products, and laminates.  A study by Budinsky et al. 
(2013) of vinyl acetate monomers (VAM) identified that VAM exposure 
produced nasal tumors in rats.  According to studies compiled from the 
Hazardous Substances Data Bank (HSDB), there is a lack of evidence 
confirming vinyl acetate as a human carcinogen.  However, vinyl acetate is 
shown to be genotoxic in human cells via in vitro studies and genotoxic to 
animals via in vivo studies; these findings resulted in the ACGIH 
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categorization of vinyl acetate as an animal carcinogen with unknown 
relevance to humans (HSDB, 2011).     
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Table 1: Chemical Information 
Constituent 
Name 
Molecular 
Formula 
Chemical 
Structure 
Known Disease 
Associations 
Mechanism/Mode 
of Action 
 
4-Ethyltoluene 
 
C9H12 
 
Rat: Ataxia  (ChemlDplus) 
Convulsions (ChemlDplus) 
Bronchitis (TOXLINE) 
Pneumonia (TOXLINE) 
Perivascular Lymphoid 
Infiltrations (PLI) 
(TOXLINE) 
 
Sister Chromatid Exchange 
(SCE) 
Gamma-Glutamyl Transferase 
(GGT) 
Lactic Acid Dehydrogenase 
(LDH) 
 
Benzanthrone 
 
C17H10O 
 
Guinea Pigs: Skin 
Sensitization Reactions 
(HSDB) 
Liver Necrosis (HSDB) 
Kidney/Bladder Lesions 
(HSDB) (Sex Unspecified) 
 
 
Lipid Peroxidation 
Oxidative Stress 
Immunotoxin 
Endocrine Disruption (EDC) 
 
Benzyl Chloride 
 
C7H7Cl 
 
Cat: Pulmonary Edema 
(ChemlDplus) 
Corneal Damage 
(ChemlDplus) 
Mice: Respiratory Depression 
(ChemlDplus) 
Rat: Respiratory Depression 
(ChemlDplus) 
Multi Species: Neoplasms  
(HSDB) 
Alkylating Agent 
Lipid Peroxidation 
Chromatid Aberration 
 
 
 
 
n-Heptane 
 
C7H16 
 
Human: CNS Depression 
(HSDB) 
Chemical Pneumonia (HSDB) 
Dermatitis (HSDB) 
Cardiac Sensitizer (HSDB) 
Hallucinations (ChemlDplus) 
Cytochrome P450 
Oxidation 
 
 
 
n-Octane 
 
C8H18 
 
Human:  
Respiratory Irritation (HSDB) 
Skin Delipidization (HSDB) 
 
Mice: CNS Depression 
(HSDB) 
Cytochrome P450 
Alkaline Phosphatase (ALP) 
Lipid Peroxidation 
 
 
 
Propene 
 
 
C3H6 
 
Dog: Cardiac Sensitizer 
(HSDB) 
Human: 
CNS Depression (HSDB) 
Eye/Skin Irritation (HSDB) 
Resp. Irritation (HSDB) 
Mice: Liver Degeneration 
(HSDB) 
Rat: Nasal Cavity Lesions 
(HSDB) 
Hydroxylate Reaction 
 
Salicylaldehyde 
 
C7H6O2 
 
Human:  
Endocrine Disruption 
(Sidhu et al. (2005)) 
 
Rat:  
Skin Irritant (HSDB) 
Enzyme Inhibition 
EDC 
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Tetrahydrofuran 
 
C4H8O 
 
Human: GI Damage (HSDB) 
Resp. Irritation (HSDB) 
CNS Depression (HSDB) 
Skin Irritation (HSDB) 
Eye Irritant (HSDB) 
 
Unknown Species:  
Liver Damage (HSDB) 
Kidney Damage (HSDB) 
Hypotension (HSDB) 
 
Oxidative Stress 
Mitogenic 
Cytochrome P450 
Hepatotoxic Aldehyde 
Oxidation 
 
 
Triphenylene 
 
C18H12 
 
No known disease 
associations found in 
literature, all associations are 
considered suspected disease 
associaitons 
 
Unknown Species:  
Eye Damage (ECHA) 
 
Skin Irritant (Haz-Map) 
No known mechanisms in 
literature 
 
 
Vinyl Acetate 
 
C4H6O2 
 
Human: 
Cardiac Irregularities (HSDB) 
Skin Irritant (HSDB) 
 
Mice:  
 
Multi Species: Oral Cancer  
(HSDB) 
 
Rats: Nasal Cancer (HSDB) 
 
Rabbit:  
Eye Irritant (HSDB) 
 
Unknown Species:  
RP Irritant (HSDB) 
CNS Depression (HSDB) 
GI Tract Tumors (HSDB) 
Uterine Tumors (HSDB) 
SCE 
Chromosome Aberration 
DNA Cross Links 
Cell Proliferation 
Cytotoxic 
Mitotic Inhibition 
Genotoxic 
 
Note: Table does not contain all chemical-disease associations, just the chemical-
disease associations used to test the Brouch Model  
*Chemical Properties obtained from ChemSpider http://www.chemspider.com 
** Mechanism transcribed from Chapter 2
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d. Diseases 
The CTD organizes associated diseases into 27 curated disease categories.  
The 27 disease categories are known as “ancestors.”   Under the “ancestors,” the 
CTD has associated “descendant” disease.  As an example, the “ancestor” disease 
of chemically induced disease has a “descendant” disease of poisoning.  The 
disease categories used in the Brouch MATLAB® ANN training were taken from 
the CTD and given a numerical value—one through 27.  Similarly to the CTD, the 
diseases associated with the testing data were selectively matched to the 27 
disease categories.  Table 2 displays the 27 disease categories used to train the 
Brouch MATLAB® ANN.  Brouch (2014) paired the chemical-disease 
associations for the curated training data set to the numerical disease categories 
found in Table 2.   
Uncurated testing chemical-disease association and numerical disease 
category pairing was accomplished using human and animal, medical surveillance 
and toxicity studies.  The medical surveillance and toxicity study findings listed in 
Table 1 were paired with the disease categories in Table 2 based on the chemical-
disease association’s comparative anatomical location.  The pairing of the 
uncurated testing data to numerical disease categories can be viewed in Appendix 
D.   
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Table 2: Disease Categories 
Disease Type/Name Numerical Disease Category 
Animal Diseases 1 
Bacterial Infections 2 
Cardiovascular Diseases 3 
Congenital, Hereditary, Neonatal Diseases 4 
Digestive System Diseases 5 
Environmental Diseases 6 
Endocrine System Diseases 7 
Eye Diseases 8 
Female Urogenital Disease 9 
Hemic and Lymphatic Diseases 10 
Immune System Diseases 11 
Male Urogenital Diseases 12 
Mental Disorders 13 
Musculoskeletal Diseases  14 
Neoplasms 15 
Nervous System Diseases 16 
Metabolic Diseases 17 
Occupational Diseases 18 
Otorhinolaryngologic Diseases 19 
Parasitic Diseases 20 
Pathological Conditions 21 
Respiratory Diseases 22 
Skin and Connective Tissue Diseases 23 
Stomatognathic Diseases 24 
Substance-Related Disorders 25 
Virus Diseases 26 
Wounds and Injuries 27 
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e. Remaining Input and Output Data 
Before the simulations could be run in MATLAB®, the chemical data and 
parameters had to be formatted to fit the requirements of the MATLAB® ANN.  
The training set of chemicals were added to a column in Microsoft® Excel®, 
followed by each chemical’s molecular weight, number of hydrogen bond donors, 
and number of hydrogen bond acceptors in the corresponding columns.  In order 
to reduce the time that the ANN needed to read the Excel® file, the data was 
copied from Excel® and pasted into a MATLAB® “.m” file.  The “.m” file listed 
the input data into a single line with an alphabetic code separating each input 
parameter.  Table 3 displays the input and output data for the curated chemical 
Acetone along with the “.m” file alphabetical code used to identify the 
parameter’s separation.  The output data for the testing set were then entered into 
the corresponding Excel® file columns.  The output data consisted of the testing 
constituent’s corresponding disease categories taken from the curated data in the 
CTD.  The output data was then copied from Excel® and pasted into the same 
MATLAB® “.m” file as the input data.  
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Table 3: Curated Input and Output Data 
 
Curated Training Data 
 
  
 
Input 
 
Output 
 
Chemical Name  
Molecular 
Weight 
 (UU) 
Hydrogen 
Acceptors 
(VV) 
Hydrogen 
Donors 
(WW) 
 
Disease Category     
    (ZZ) 
 
Acetone 58.08 
 
1 
 
0 
 
9 
 
 
Acetone 58.08 
 
1 
 
0 
 
12 
 
 
Acetone 58.08 
 
1 
 
0 
 
15 
 
 
Acetone 58.08 
 
1 
 
0 
 
16 
 
 
Acetone 58.08 
 
1 
 
0 
 
17 
 
 
Acetone 58.08 
 
1 
 
0 
 
25 
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The number of CTD curated chemical-disease associations determined the number of rows used for each training 
chemical.  Using the CTDs curated chemical-disease associations for acetone; the chemical-disease associations were 
categorized based upon the CTDs 27 disease categories.  As seen in Table 3, Acetone has six chemical-disease 
associations.  Since acetone has six chemical-disease associations, there are six rows containing acetone’s molecular 
weight, number of hydrogen bond acceptors, number of hydrogen donor donors, and the corresponding chemical-disease 
association numerical value.  The same process was used for the testing set.  However, the testing data set disease 
associations were not used as outputs, since the MATLAB® ANN was set to predict the associated diseases as an output.  
An example of the data used for the testing data set can be viewed in Table 4 for Triphenylene.  A copy of the complete 
input and output tables for the training and testing data sets can be found in Appendix A and Appendix B. 
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Table 4: Uncurated Input and Output Data 
 
 
Uncurated Testing Data 
 
  
Input 
 
 
Output 
     
 
Chemical                    
(Synonym)                          
(CAS #)  
 
 
MW 
(CC) 
Hydrogen 
Bond 
 
ANN 
 
 
Known 
 
Acceptor 
(DD) 
Donor 
(EE) 
Derived 
Disease 
(GG) 
 
Rounded 
Disease 
(HH) 
 
Disease 
Category 
 (II) 
 
Disease Name  
 
 
 
Triphenylene 
(Isochrysene) 
(217-59-4) 
 
228.29 0 0 4.5 5 8 Eye Disease 
 
Triphenylene 
(Isochrysene) 
(217-59-4) 
228.29 0 0 6 6 23 Skin Disease 
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2. Artificial Neural Network  
ANNs are grouped into two categories: feed-forward and regression.  The Brouch 
MATLAB® ANN is a feed-forward network.  Feed-forward networks are organized 
into layers with connections that flow only in one direction from layer to layer (Jain 
et al., 1996).  The specific type of feed-forward ANN used in the Brouch MATLAB® 
ANN is a Multilayer Preceptor (MLP).  MLPs have three layers: an input layer, a 
hidden layer, and an output layer (Shamisi et al., 2011).  MLPs may have one or more 
hidden layers which allow the ANN to learn complex non-linear functions (Lee and 
Lucas, 2014). 
In order to learn, feed-forward ANNs need to be trained.  Training a feed-forward 
MLP involves back-propagation.  Back-propagation calculates the difference between 
the actual outputs and predicated outputs and is propagated from the output nodes 
backwards to the nodes in the previous layer.  Back-propagation is accomplished to 
improve weights during training.  Per Adrian Shepherd, a good network will classify 
patterns similar to, but not identical to, patterns in the training set (Shepherd, 1999).  
In order to establish well-defined training sets, the number of elements in the input, 
the target, and the output layers must match.  
In order to create a network that can generalize the number of training patterns, 
the training patterns must be compared to the network weights.  If the network weight 
is greater than the number of training patterns, the ANN may become too powerful 
and begin over-fitting.  The number of hidden layers may also affect network 
generalization.  Having too few hidden networks can leave the network unable to 
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learn.  Having too many hidden layers can result in poor generalization.  Lastly, the 
number of training iterations performed can also alter the network.  Having too little 
iteration, the network will not be able to import data from the training set.  In 
contrast, having too many iterations will result in the network over-training.  
In 2014, Brouch developed and programmed a MATLAB® ANN.  The formulas 
were determined by the type of training function specified for the network to use 
during simulation.  The weights and biases were placed on the input data, as the 
network was tested.  After testing the known input and output data with the training 
function formulas, weight, and biases, the network-derived outputs were compared to 
the actual output formulated from relevant literature and research.  
3. Simulations 
Four types of simulations were run through the Brouch MATLAB® ANN: the 
effect of hidden layers on ANN performance; the effect of the TVT ratios on ANN 
performance; the effect of chemical structure on ANN performance; and constituent-
specific ANN-based predictions for uncurated constituent found in burn pit 
emissions.  This section will briefly describe the type of simulation.  Simulation 
results can be seen and are recorded in Chapter 4 of this thesis. 
a. The effect of hidden layers on ANN performance 
Initial simulations included running all uncurated constituent simultaneously 
through the ANN model.  Upon input into the model, the data were divided into 
three subsets: training, validation, and testing (TVT).  The TVT used for the 
initial ANN mode simulations consisted of 70% of the training data, 15% of the 
validation data, and 15% of the testing data.  TVT can also be referenced or 
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written as 70/15/15.  The input into the model was processed through a hidden 
layer, before the output was generated.  Hidden layers consist of hidden neurons 
that are neither in the input layer nor the output layer and can be 
conceptualized/visualized in Figures 1 and 2.  The utilization of additional hidden 
layers can be used to determine if the additional layers would increase processing 
power and system flexibility.  However, additional hidden layers can add 
unwanted or unneeded complexity in the training algorithm.  If there are too many 
hidden layers, there may be more equations than there are free variables resulting 
in the system being over specified, and the ANN becomes incapable of 
generalization.  If the ANN has too few hidden layers, then the lessened amount 
of hidden neurons can prevent the system from properly fitting the input data and 
reduces the robustness of the system.  The initial model simulations were capped 
at five hidden layers to optimize ANN output.  Later, simulations were capped at 
two hidden layers to optimize the run time of the model. 
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Figure 1: Basic ANN Layout  
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Figure 2: Detailed ANN Layout 
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b. The effect of the TVT ratios on ANN performance 
In order to determine the effect of different training, validation, and testing 
(TVT) ratios on ANN performance, three TVT ratios were selected and used to 
run the Brouch ANN: 60/20/20, 70/15/15, and 80/10/10.  The training subset 
represents the percentage of data selected from the “curated training data” that 
was used to train the model.  The first number subset (60, 70, or 80) in the TVT 
ratio represents the percentage of data used to train the model from the training 
set.  Training occurs by pairing inputs with expected outputs, and is used to 
compute the gradient, the network weights, and the networks biases.  While 
training the model, the validation error is monitored to prevent the model from 
over fitting the training data and is derived from the second set of numbers in the 
TVT ratio (20, 15, or 10).  The Brouch ANN uses the uncurated testing data set to 
evaluate the network performance.  The third subset of numbers from the TVT 
ratio is the testing subset (20, 15, or 10).  The testing subset represents the 
percentage of data selected from the uncurated testing data that was used to 
generate the models output or results.   
c. The effect of chemical structure on ANN performance 
Chemicals with similar chemical structure were run through the model at HL 
=2 and all three TVTs.  The three different TVTs used were 60/20/20, 70/15/15, 
and 80/10/10.  The first set of similar structure chemicals (Group 1) included 
chemicals that contained hydrocarbon chains.  The chemicals in Group 1 
included: n-heptane, n-octane, and propene.  The second set of similar-structure 
chemicals (Group 2) included benzene ring structures.  The chemicals in Group 2 
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included: 4-ethyltoluene, benzyl chloride, benzanthrone, salicylaldehyde, and 
triphenylene.  Chemical structure similarities can be seen in Table 1.   
d. Chemical-specific ANN-based predictions for uncurated constituents found 
in burn pit emissions 
Each uncurated constituent was run through the model individually using HL 
=2 and all three TVTs: 60/20/20, 70/15/15, and 80/10/10.        
4. Analysis and Results 
This section will briefly describe how the analysis and results from the 
MATLAB® ANN were processed.  Full analysis and results are recorded in Chapter 4 
of this thesis.  Once all simulations were complete, the output data was written from 
the MATLAB® ANN into a Microsoft® Excel® file for analysis.  While in Microsoft® 
Excel®, the ANN output of predicted disease was plotted/graphed against the known 
associated disease.  Once plotted, Excel® was used to calculate the correlation 
coefficient (R2).  The correlation coefficient indicates the nature and strength of the 
relationship between the Predicted Disease Category and the Actual Disease 
Category.   
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IV. Results and Discussion 
Overview 
The output generated by the Brouch MATLAB® ANN was recorded in a 
Microsoft® Excel® scatter plot.  The scatter plot was used to graphically represent the 
relationship between the ANN predicted disease category plotted on the Y-Axis and the 
known disease category plotted on the X-Axis.  The regression equation and the 
correlation coefficient, or R2, was calculated using Microsoft® Excel®.  The correlation 
coefficient indicates the nature and strength of the relationship between the predicted 
disease category and the known disease category.  Ultimately, precise agreement between 
the ANN-predicted disease category and the known disease category was the goal.  A 
correlation coefficient at, or near, the value of one indicates a positive correlation.  
However, a correlation coefficient at or near the value of one does not indicate that the 
model can accurately predict chemical disease associations.  
The effect of hidden layers on ANN performance 
Figure 3 displays the effect of hidden layers on the ANN performance for nine of 
the ten uncurated constituents found in burn pit emissions.  The uncurated constituent, 
Triphenylene, was excluded from the hidden layer performance modeling due to the 
absence of known chemical-disease associations.  The X-Axis shows the disease category 
and the Y-Axis shows the predicted disease category that was generated by the ANN.  
The diagonal line shown on the graph is the reference for precise agreement between the 
actual and predicted disease categories.  The model output was not in agreement with the 
actual disease categories and was widely scattered, regardless of the number of hidden 
layers.  Numerous incorrect disease associations were observed. When HL =1, there was 
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a misidentification rate of 84% (37 out of 44), including three misidentifications for 
chemicals causing nutritional and metabolic diseases and four misidentifications for 
chemicals causing hemic and lymphatic diseases.  Similar observations were made when 
more than one hidden layer was used.  When HL =2, there was a misidentification rate of 
73% (32 out of 44), including one misidentifications for chemicals causing 
stomatognathic diseases and three misidentifications for chemicals causing parasitic 
diseases.  When HL =3, there was a misidentification rate of 93% (41 out of 44), 
including five misidentifications for chemicals causing bacterial infections and mycoses 
and for misidentifications for chemicals causing musculoskeletal diseases.  When HL =4, 
there was a misidentification rate of 91% (40 out of 44) including five misidentifications 
for chemicals causing animal diseases and four misidentifications for chemicals causing 
environmental disorders.  When HL =5, there was a misidentification rate of 89% (39 out 
of 44), including four misidentifications for chemicals causing immune system diseases 
and two misidentifications for chemicals causing mental disorders.  The regressions of 
each number of hidden layers exhibited coefficients of determination that were 0.1 or less 
and may be viewed in Table 5 with each hidden layers regression equation.  In light of 
the high misidentification rates and the low coefficients of determination, these results 
indicate that the Brouch ANN model lacks the general predictive capability that is needed 
to screen constituents that are found in burn pit emissions. 
To verify consistent model results each HL simulation was run in duplicate.  In 
order to compare the original and duplicate run, the correlation coefficient (R2) for each 
run was calculated.  Using the R-values from the original and duplicate run, the HL z-
score and probability values were calculated (Table 6).  A probability value of < 0.05 
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indicates that the two correlation coefficients for each HL differ significantly.  All 
comparative HL simulations produced probability values in excess of 0.85 indicating that 
the original and duplicate simulations were statistically similar, demonstrating the 
internal consistency and reliability of the Brouch ANN.   
The effect of additional hidden layers on the performance of the ANN resulted in 
the unwanted added complexity in the training algorithm.  During the hidden layer 
addition simulations, the network increased training time, which resulted in the network 
shutting down.  Specifically during the HL =4 simulation, the run time lasted longer than 
24 hours.  Due to this issue, each chemical was run independently at HL =2.  The 
selection of HL =2 maintained simulation run times between 20 and 40 minutes.  
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Figure 3: Original ANN Output 
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Table 5: The effect of the number of hidden layers on ANN performance; Regressions and coefficients of determination 
 
Number of Hidden 
Layers 
 
 
Regression 
Equation 
 
 
Coefficient of  
Determination (R2) 
 
1 
 
y = 0.0016x + 10.787 
 
 
0.000003 
 
2 
 
y = 0.0016x + 13.229 
 
 
0.000003 
 
3 
 
y = 0.001x + 7.9777 
 
 
0.000003 
 
4 
 
y = 0.0021x + 6.5718 
 
 
0.000005 
 
5 
 
y = -0.0256x + 9.5932 
 
 
0.0009 
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Table 6: Determining model reliability using HL simulation comparisons; Regression equations, coefficients of 
determination, correlation coefficients, z-scores, and probability value  
HL Number of 
Simulations 
Regression 
Equation 
Coefficient of 
Determination 
(R2) 
Correlation 
Coefficient 
(R) 
z-Score Probability 
Value 
 
 
1 
 
1 
 
y = 0.0016x + 10.787 
 
0.000003 
 
0.0017 
 
 
0.145 
 
 
0.88  
2 
 
y = 0.0286x + 6.4541 
 
0.1459 
 
-0.0303 
 
 
2 
 
1 
 
y = 0.0016x + 13.229 
 
0.000003 
 
0.0017 
 
 
0.191 
 
 
0.85  
2 
 
y = 0.3548x + 7.8632 
 
0.1439 
 
-0.0404 
 
 
3 
 
1 
 
y = 0.001x + 7.9777 
 
0.000003 
 
0.0017 
 
 
0.124 
 
 
0.90  
2 
 
y = 0.2139x + 4.5353 
 
0.1435 
 
-0.0257 
 
 
4 
 
1 
 
y = 0.0021x + 6.5718 
 
0.000005 
 
0.0023 
 
 
0.164 
 
 
0.87  
2 
 
y = 0.2303x + 4.1325 
 
0.1435 
 
-0.0339 
 
 
5 
 
1 
 
y = -0.0256x + 9.5932 
 
0.0009 
 
-0.0294 
 
 
0.117 
 
 
0.91  
2 
 
y = 0.3263x + 4.0263 
 
0.0022 
 
-0.0553 
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The effect of the TVT ratios on ANN performance 
Figures 7 – 11 in Appendix A display the TVT ratio comparisons for nine of the 
ten uncurated constituents found in burn pit emissions for HL = 1 through HL =5.  The 
uncurated constituent, Triphenylene, was excluded from the TVT performance modeling 
due to the absence of known chemical-disease associations.  The X-Axis displays the 
disease category and the Y-Axis displays the predicted disease category that was 
generated by the ANN.  The diagonal line shown on the graph is the reference for precise 
agreement between the actual and predicted disease categories.  The model output for all 
TVT ratio comparisons was not in agreement with the actual disease categories and was 
widely scattered, regardless of the number of hidden layers.  Numerous incorrect disease 
associations were observed.   
The first TVT comparison evaluated the 60/20/20, 70/15/15, and 80/10/10 TVT 
ratios at HL =1.  When the 60/20/20 TVT ratio was used there was a misidentification 
rate of 100% (44 out of 44).  When HL=1 and the 60/20/20 TTV was used the model 
predicted only negative disease category values.  When the 70/15/15 TVT ratio was used 
there was a misidentification rate of 84% (37 out of 44), including three 
misidentifications for chemicals causing nutritional and metabolic disorders and two 
misidentifications for chemicals causing occupational diseases.  When the 80/10/10 TVT 
ratio was used there was a misidentification rate of 84% (37 out of 44), including two 
misidentifications for chemicals causing parasitic diseases and three misidentifications 
for chemicals causing immune system diseases.  The TVT comparisons for HL =1 can be 
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viewed in Figure 7 of Appendix A.  Similar observations were made when more than one 
hidden layer was used.   
The second TVT comparison evaluated the 60/20/20, 70/15/15, and 80/10/10 
TVT ratios at HL =2.  When the 60/20/20 TVT ratio was used there was a 
misidentification rate of 100% (44 out of 44).  When HL=2 and the 60/20/20 TTV was 
used, the model predicted only negative disease category values.  When the 70/15/15 
TVT ratio was used, there was a misidentification rate of 77% (34 out of 44), including 
two misidentifications for chemicals causing pathological conditions and two 
misidentifications for chemicals causing nutritional and metabolic diseases.  When the 
80/10/10 TVT ratio was used there was a misidentification rate of 75% (33 out of 44), 
including two misidentifications for chemicals causing substance-related disorders and 
one misidentifications for chemicals causing virus diseases.  The TVT comparisons for 
HL =2 can be viewed in Figure 8 of Appendix A.   
The third TVT comparison evaluated the 60/20/20, 70/15/15, and 80/10/10 TVT 
ratios at HL =3.  When the 60/20/20 TVT ratio was used there was a misidentification 
rate of 100% (44 out of 44).  When HL=3 and the 60/20/20 TTV was used the model 
predicted only negative disease category values.  When the 70/15/15 TVT ratio was used 
there was a misidentification rate of 86% (38 out of 44), including four misidentifications 
for chemicals causing musculoskeletal diseases and two misidentifications for chemicals 
causing neoplasms.  When the 80/10/10 TVT ratio was used there was a misidentification 
rate of 84% (37 out of 44), including five misidentifications for chemicals causing 
bacterial infections and mycoses and three misidentifications for chemicals causing 
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mental disorders.  The TVT comparisons for HL =3 can be viewed in Figure 9 of 
Appendix A.     
The fourth TVT comparison evaluated the 60/20/20, 70/15/15, and 80/10/10 TVT 
ratios at HL =4.  When the 60/20/20 TVT ratio was used there was a misidentification 
rate of 96% (42 out of 44), including four misidentifications for chemicals causing 
bacterial infections and mycoses.  When the 70/15/15 TVT ratio was used there was a 
misidentification rate of 87% (39 out of 44), including four misidentifications for 
chemicals causing immune diseases and three misidentifications for chemicals causing 
animal diseases.  When the 80/10/10 TVT ratio was used there was a misidentification 
rate of 86% (38 out of 44), including three misidentifications for chemicals causing 
hemic and lymphatic diseases and four misidentifications for chemicals causing mental 
disorders.  The TVT comparisons for HL =4 can be viewed in Figure 10 of Appendix A.       
The final TVT comparison evaluated the 60/20/20, 70/15/15, and 80/10/10 TVT 
ratios at HL =5.  When the 60/20/20 TVT ratio was used there was a misidentification 
rate of 98% (43 out of 44).  When HL=3 and the 60/20/20 TTV was used the model 
predicted 29 negative disease category values.  When the 70/15/15 TVT ratio was used 
there was a misidentification rate of 91% (40 out of 44), including four misidentifications 
for chemicals causing bacterial infections and mycoses and two misidentifications for 
chemicals causing parasitic diseases.  When the 80/10/10 TVT ratio was used there was a 
misidentification rate of 91% (40 out of 44) including four misidentifications for 
chemicals causing environmental disorders and one misidentification for chemicals 
causing substance-related disorders.  The TVT comparisons for HL =5 can be viewed in 
Figure 11 of Appendix A.         
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The regressions for each TVT ratio exhibited coefficients of determination that 
were 0.1 or less and are displayed in Table 7.  Considering the high misidentification 
rates and the low coefficients of determination, the TVT comparison results indicate that 
the TVT ratio does not impact the accuracy of the Brouch ANN.  To further demonstrate 
this point, the bar graph in Figure 4 displays all TVT comparisons for each of the hidden 
layers tested, where the X-Axis displays the results of each hidden layers TVT 
comparisons, and the Y-Axis displays the coefficient of determination (R2).   
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Table 7: The effect of TVT ratios on ANN performance; Regressions and misidentification ratios 
 
 
HL 
Regression Equation Misidentification Ratio 
 
60/20/20 
 
70/15/15 
 
80/10/10 
 
60/20/20 
 
70/15/15 
 
80/10/10 
 
1 
 
y = 0.0123x + 4.908 
 
y = -0.026 + 11.059 
 
y = -0.0266x + 11.227 
 
44:44 
 
37:44 
 
37:44 
 
2 
 
y = -5E-05x – 0.0086 
 
y = -0.0495x + 13.854 
 
y = -0.0384x + 13.874 
 
44:44 
 
34:44 
 
33:44 
 
3 
 
y = 0.0293x – 9.2427 
 
y = -0.0184x + 8.107 
 
y = -0.028x + 8.2673 
 
44:44 
 
38:44 
 
37:44 
 
4 
 
y = -0.0521x + 2.8549 
 
y = -0.042x + 6.5502 
 
y = -0.021x + 7.9868 
 
42:44 
 
39:44 
 
38:44 
 
5 
 
y = -0.021x – 0.8091 
 
y = -0.0485x + 9.8617 
 
y = -0.0468x + 10.02 
 
43:44 
 
40:44 
 
40:44 
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Figure 4: TVT Comparison across all HLs 
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The effect of chemical structure on ANN performance 
Figures 5 and 6 show the effects of chemical structure on the performance of the 
ANN for eight of the ten uncurated constituents found in burn pit emissions at HL =2.   
The eight uncurated constituents tested contained either benzene rings or hydrocarbon 
chains.  The two excluded uncurated constituents; tetrahydrofuran and vinyl acetate, were 
excluded from the similar structure performance modeling due to their chemical 
structure.  The X-Axis displays the known disease category and the Y-Axis displays the 
predicted disease category that was generated by the ANN.  The diagonal line shown on 
the graph is the reference for precise agreement between the actual and predicted disease 
categories.  The model output was not in agreement with the actual disease categories and 
was widely scattered, regardless of the TVT ratio.  Numerous incorrect disease 
associations were observed.  
Group 1 – Chemical Structures containing Hydrocarbon Chains 
The chemicals in Group 1 contained hydrocarbon chains and included the 
following chemicals: n-heptane, n-octane, and propene.  Group 1 chemicals were 
evaluated at the 60/20/20, 70/15/15, and 80/10/10 TVT ratios at HL =2.  
Comparing the hydrocarbon chained chemicals from the Group 1 data set to the 
Curated Training Data set; the Curated Training Data set did not contain 
chemicals that were structurally related to the Group 1 data set.   
When Group 1 chemicals were modeled at the 60/20/20 TVT ratio there 
was a misidentification rate of 100% (15 out of 15), including four 
misidentifications for chemicals causing bacterial infections and mycoses and 
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three misidentifications for chemicals causing endocrine system diseases.  When 
the Group 1 chemicals were modeled at the 70/15/15 TVT ratio there was a 
misidentification rate of 73% (11 out of 15), including two misidentifications for 
chemicals causing female urogenital diseases and pregnancy complications.  
When compared to the original ANN output at the 70/15/15 TVT ratio for HL =2 
simulation captured in Figure 3, the two simulations share similar 
misidentification ratios.  The chemicals in Group 1 at the 70/15/15 for HL =2 had 
a misidentification rate of 73% (11 out of 15), while the original ANN output at 
the 70/15/15 TVT for HL =2 had a misidentification rate of 73% (32 out of 44).  
When Group 1 chemicals were modeled at the 80/10/10 TVT ratio there was a 
misidentification rate of 80% (12 out of 15), including two misidentifications for 
chemicals causing environmental disorders and two misidentifications for 
chemicals causing hemic and lymphatic diseases.  The Group 1 TVT comparisons 
at HL =2 can be viewed in Figure 5.   
Group 2 – Chemical Structures containing Benzene Rings 
The chemicals in Group 2 contained benzene rings and included the 
following chemicals: 4-ethyltoluene, benzyl chloride, benzanthrone, 
salicylaldehyde, and triphenylene.  Group 2 chemicals were evaluated at the 
60/20/20, 70/15/15, and 80/10/10 TVT ratios at HL =2.  Comparing the benzene 
ring containing chemicals from the Group 2 data set to the curated training data 
set, 55% (41 out of 75), chemicals from the Curated Training Data contained 
benzene ring structures.     
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When group 2 chemicals were modeled at the 60/20/20 TVT ratio there 
was a misidentification rate of 86% (12 out of 14), including two 
misidentifications for chemicals causing congenital, hereditary, neonatal diseases 
and abnormalities and three misidentifications for chemicals causing immune 
system diseases.  When Group 2 chemicals were modeled at the 70/15/15 TVT 
ratio there was a misidentification rate of 100% (14 out of 14).  The 70/15/15 
TVT ratio predicted negative disease category values less than one.  When 
compared to the original ANN output at the 70/15/15 TVT ratio for HL =2 
simulation captured in Figure 3, the two simulations did not share similar 
misidentification ratios.  The chemicals in Group 2 at the 70/15/15 for HL =2 had 
a misidentification rate of 100% (14 out of 14), while the original ANN output at 
the 70/15/15 TVT for HL =2 had a misidentification rate of 73% (32 out of 44).    
When Group 2 chemicals were modeled at the 80/10/10 TVT ratio there was a 
misidentification rate of 86% (12 out of 14) including four misidentifications for 
chemicals causing immune system diseases and three misidentifications for 
chemicals causing eye diseases.  The Group 2 TVT comparisons at HL =2 can be 
viewed in Figure 6.   
The regression equations and coefficients of determination for Groups 1 
and 2 are displayed in Table 8.  The regressions for each groups TVT ratio 
displayed coefficients of determination that were 0.1 or less.  Considering the 
high misidentification rates and the low coefficients of determination, the similar 
chemical structure comparisons indicate that a chemical structure similarity does 
not impact the accuracy of the Brouch ANN.  At this time, it is recommended that 
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the curated training data set be expanded to include chemicals that contain 
hydrocarbon chains.  
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Figure 5: Similar Chemical Structure - Group 1: Hydrocarbon Chains 
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Figure 6: Similar Chemical Structure - Group 2: Benzene Rings 
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Table 8: The effect of Chemical Structure on ANN performance; Regressions and misidentification ratios 
 
 
Group  
Regression Equation Misidentification Ratio 
 
60/20/20 
 
70/15/15 
 
80/10/10 
 
60/20/20 
 
70/15/15 
 
80/10/10 
 
1 
 
y = 0.018x + 2.9561 
 
y = 0.1643x + 7.6949 
 
y = 0.2238x + 4.8685 
 
15:15 
 
11:15 
 
12:15 
 
2 
 
y = 0.1313x + 7.2329 
 
y = -0.0008x + 0.1094 
 
y = 0.0472x + 8.1226 
 
12:14 
 
14:14 
 
12:14 
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Chemical-specific ANN-based predictions for uncurated constituents found in burn 
pit emissions 
Misidentification Ratios 
Figures 12 through 21 in Appendix B display the effects of individual 
constituents on the ANN performance for the ten uncurated constituents found in 
burn pit emissions at HL =2.  All uncurated constituents were evaluated at the 
60/20/20, 70/15/15, and 80/10/10 TVT ratios.  The X-Axis displays the known 
disease category and the Y-Axis displays the predicted disease category that was 
generated by the ANN.  The diagonal line shown on the graph is the reference for 
precise agreement between the actual and predicted disease categories.  The 
model output was not in agreement with the actual disease categories and was 
widely scattered, regardless of the TVT ratio.  Numerous incorrect disease 
associations were observed.  Table 9 displays the uncurated constituents, disease 
associations, mechanism of disease, and the misidentification ratios for the 
individual uncurated constituent simulations.   
4-Ethyltoluene 
When the 60/20/20 TVT ratio was used there was a 
misidentification rate of 100% (3 out of 3), to include the misidentification 
of bacterial infections, endocrine system, and metabolic diseases.  When 
the 70/15/15 TVT ratio was used there was a misidentification rate of 
100% (3 out of 3), to include the misidentification of female urogenital 
diseases, and neoplasms.  When the 80/10/10 TVT ratio was used there 
was a misidentification rate of 100% (3 out of 3), to include the 
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misidentification of digestive system, endocrine system, and eye diseases.  
The TVT comparisons for 4-ethyltoluene can be viewed in Figure 12 of 
Appendix B.   
Benzanthrone 
When the 60/20/20 TVT ratio was used there was a 
misidentification rate of 100% (4 out of 4), to include the misidentification 
of immune system diseases and three model predictions for negative 
disease category values.  When the 70/15/15 TVT ratio was used there 
was a misidentification rate of 75% (3 out of 4), to include the 
misidentification of digestive system disease, and environmental 
disorders.  When the 80/10/10 TVT ratio was used there was a 
misidentification rate of 100% (4 out of 4), to include the misidentification 
of eye, immune system, and musculoskeletal diseases.  The TVT 
comparisons for benzanthrone can be viewed in Figure 13 of Appendix B.   
Benzyl Chloride  
When the 60/20/20 TVT ratio was used there was a 
misidentification rate of 100% (3 out of 3), to include the misidentification 
of immune system diseases and two model predictions for negative disease 
category values.  When the 70/15/15 TVT ratio was used there was a 
misidentification rate of 67% (2 out of 3), to include the misidentification 
of environmental disorders, and digestive system diseases.  When the 
80/10/10 TVT ratio was used there was a misidentification rate of 67% (2 
out of 3), to include the misidentification of immune system and 
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musculoskeletal diseases.  The TVT comparisons for benzyl chloride can 
be viewed in Figure 14 of Appendix B.   
n-Heptane   
When the 60/20/20 TVT ratio was used there was a 
misidentification rate of 80% (4 out of 5), to include the misidentification 
of neoplasms, immune system, and musculoskeletal diseases.  When the 
70/15/15 TVT ratio was used there was a misidentification rate of 80% (4 
out of 5), to include the misidentification of environmental, endocrine 
system, and eye diseases.  When the 80/10/10 TVT ratio was used there 
was a misidentification rate of 80% (4 out of 5), to include the 
misidentification of cardiovascular, congenital, hereditary, neonatal, 
environmental, hemic, and lymphatic diseases.  The TVT comparisons for 
n-heptane can be viewed in Figure 15 of Appendix B.   
n-Octane 
When the 60/20/20 TVT ratio was used there was a 
misidentification rate of 100% (3 out of 3), to include the misidentification 
of congenital, hereditary, neonatal, animal, and cardiovascular diseases.  
When the 70/15/15 TVT ratio was used there was a misidentification rate 
of 100% (3 out of 3), to include the misidentification of animal diseases, 
bacterial infections, and one model prediction for negative disease 
category values.  When the 80/10/10 TVT ratio was used there was a 
misidentification rate of 100% (3 out of 3), to include the misidentification 
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of neoplasms, endocrine system, and immune system diseases.  The TVT 
comparisons for n-octane can be viewed in Figure 16 of Appendix B.   
Propene 
When the 60/20/20 TVT ratio was used there was a 
misidentification rate of 71% (5 out of 7), to include the misidentification 
of congenital, hereditary, neonatal, endocrine system, and environmental 
diseases.  The 60/20/20 TVT ratio also produced the misidentification of 
bacterial infections, and one model prediction for negative disease 
category values.  When the 70/15/15 TVT ratio was used there was a 
misidentification rate of 71% (5 out of 7), to include the misidentification 
of animal, immune system, environmental, female urogenital, hemic, and 
lymphatic diseases.  When the 80/10/10 TVT ratio was used there was a 
misidentification rate of 71% (5 out of 7), to include the misidentification 
of animal, endocrine system, female urogenital and musculoskeletal 
diseases.  The TVT comparisons for propene can be viewed in Figure 17 
of Appendix B.   
Salicylaldehyde 
When the 60/20/20 TVT ratio was used there was a 
misidentification rate of 100% (2 out of 2), to include the misidentification 
of environmental diseases, and one model prediction for negative disease 
category values.  When the 70/15/15 TVT ratio was used there was a 
misidentification rate of 100% (2 out of 2), to include the misidentification 
of immune system diseases.  When the 80/10/10 TVT ratio was used there 
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was a misidentification rate of 100% (2 out of 2), to include the 
misidentification of environmental diseases.  The TVT comparisons for 
salicylaldehyde can be viewed in Figure 18 of Appendix B.   
Tetrahydrofuran 
When the 60/20/20 TVT ratio was used there was a 
misidentification rate of 75% (6 out of 8), to include the misidentification 
of substance-related disorders, endocrine system, and metabolic diseases.  
When the 70/15/15 TVT ratio was used there was a misidentification rate 
of 50% (4 out of 8), to include the misidentification of neoplasms, 
substance-related disorders, and metabolic diseases.  When the 80/10/10 
TVT ratio was used there was a misidentification rate of 63% (5 out of 8), 
to include the misidentification of bacterial infections, endocrine system, 
eye, and musculoskeletal diseases.  The TVT comparisons for 
tetrahydrofuran can be viewed in Figure 19 of Appendix B.   
Triphenylene 
When the 60/20/20 TVT ratio was used there was a 
misidentification rate of 100% (2 out of 2), to include the misidentification 
of immune system diseases, and one model prediction for negative disease 
category values.  When the 70/15/15 TVT ratio was used there was a 
misidentification rate of 100% (2 out of 2), to include the misidentification 
of digestive system, and environmental diseases.  When the 80/10/10 TVT 
ratio was used there was a misidentification rate of 100% (2 out of 2), to 
include the misidentification of immune system, and eye diseases.  The 
          
86 
TVT comparisons for triphenylene can be viewed in Figure 20 of 
Appendix B.   
Vinyl Acetate 
When the 60/20/20 TVT ratio was used there was a 
misidentification rate of 89% (8 out of 9), to include the misidentification 
of bacterial infections, neoplasms, pathological conditions, congenital 
diseases, hereditary diseases, neonatal disease, and one model prediction 
for negative disease category values.  When the 70/15/15 TVT ratio was 
used there was a misidentification rate of 89% (8 out of 9), to include the 
misidentification of bacterial infections, environmental diseases, one half-
value model prediction, and three model predictions for negative disease 
category values.  When the 80/10/10 TVT ratio was used there was a 
misidentification rate of 89% (8 out of 9), to include the misidentification 
of animal, endocrine system, immune system, and metabolic diseases, 
along with the prediction of two negative disease category values.  The 
TVT comparisons for vinyl acetate can be viewed in Figure 21 of 
Appendix B.   
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Table 9: Constituent specific ANN-based predictions for uncurated chemicals found in burn pit emissions: Disease 
causation, mechanisms, and misidentification ratios 
Constituents Disease  
Causation 
Mechanisms 
Of Action 
Misidentification Ratio 
60/20/20 70/15/15 80/10/10 
4-ethyltoluene 16, 22, 23 Sister Chromatid Exchange (SCE), Gamma-Glutamyl 
Transferase (GGT), and Lactic Acid Dehydrogenase 
(LDH) 
3:3 3:3 3:3 
Benzanthrone 5, 9, 12, 23 Lipid Peroxidation, Oxidative Stress, Endocrine Disruption 
(EDC), Immunotoxin 4:4 3:4 4:4 
Benzyl Chloride 5, 22, 23 Alkylating Agent, Lipid Peroxidation, Chromatid 
Aberration 
 
3:3 2:3 2:3 
n-Heptane 3, 5, 16, 22, 23 Cytochrome P450, Oxidation 
 4:5 4:5 4:5 
n-Octane 16, 22, 23 Cytochrome P450, Alkaline Phosphatase (ALP), Lipid 
Peroxidation 
 
3:3 3:3 3:3 
Propene 3, 5, 8, 16, 19, 22, 
23 
Hydroxylate Reaction 5:7 5:7 5:7 
Salicylaldehyde 7, 23 Enzyme Inhibition, EDC 2:2 2:2 2:2 
Tetrahydrofuran 3, 5, 8, 9, 12, 16, 
22, 23 
Oxidative Stress, Mitogenic, Cytochrome P450, 
Hepatotoxic Aldehyde 6:9 4:9 5:9 
Triphenylene 8, 23 No known mechanisms in literature 2:2 2:2 2:2 
Vinyl Acetate 3, 5, 8, 9, 16, 19, 
22, 23, 24 
SCE, Chromosome Aberration, DNA Cross Links, Cell 
Proliferation, Cytotoxic, Mitotic Inhibition, Genotoxic 
 
8:9 8:9 8:9 
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Data Gaps 
Chemical-Disease-Mechanism Associations 
The chemical-disease associations used to train the Brouch ANN 
model were selected due to their known associations described in the 
CTD.  However, the chemical-disease associations selected to test the 
Brouch ANN model were derived from suspected disease-associations due 
to the limited nature of available literature and research.  The high 
misidentification ratios indicate that more data is needed for ANN training 
with uncurated constituents.   
 Chemical Mixtures 
 
Due to the limited data on chemical mixtures and their side effects, 
the Brouch ANN was not trained to predict disease for chemical mixtures.  
As it stands, the ten uncurated burn pit constituents used to test the Brouch 
ANN enter the body in the form of a mixture.  However, the burn pit 
constituents were modeled as individual chemical components due to the 
trained ability of the model.  With the understanding that each chemical 
maintains its own toxic effect inside the body, the chemical combination 
present in mixtures causes the mechanisms and health predictions to 
become increasingly complicated.  The combination of mechanisms and 
toxic effects may result in the additive, synergistic, or potentiating effects.  
Additive effects occur when chemicals have similar toxic effects, produce 
a combined effect that is equal to the sum of the chemicals separate 
          
89 
effects.  Synergistic effects occur when the chemical combination 
produces a health effect that is greater than the sum of the individual 
chemical effects.  Potentiating effects occur when an effect of one 
chemical is increased by the exposure to a second chemical.  Data and 
chemical testing is limited on these types of chemical interactions 
resulting in the inability to model the health effects of chemical mixtures.  
Expanding the training data set to include chemical mixtures may help 
overcome this limitation.    
Further Testing 
Further testing is recommended for the burn pit constituents with 
R2 values greater than 0.8.  The constituents with an R2 value greater than 
0.8 include: 4-ethyltoluene, benzanthrone, n-heptane, n-octane, 
salicylaldehyde, and triphenylene.  The six constituents identified above 
can be viewed in Table 10.  These six constituents should be prioritized to 
help further develop predictive ANN models for human health force 
support.  
The American Chemistry Council’s (ACC’s) 2011 Chemical 
Prioritization Screening Approach (ACC, 2011) was adopted to prioritize 
the six uncurated burn pit emission constituents.  In order to rank and 
assign a priority to a constituent, the ACC recommends identifying the 
following: the constituent’s toxicity, carcinogenicity, endocrine disruptor 
status, and available data.  These items were used to rank the health 
hazards for the six uncurated burn pit constituents and can be seen in 
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Table 10.  The persistency and bioaccumulation variable for each 
constituent were also used as indicators of exposure.  The persistency and 
bioaccumulation criteria from the ACC approach, recommended 
distinguishing between persistent and non-persistent chemicals using the 
following criteria: volatile chemicals are maintaining a vapor pressure > 
1000 Pa.  Persistent versus non-persistent chemicals were differentiated 
using a chemical half-life in air.   
A constituent was not considered persistent if the air half-life was 
< 2 days.  The air half-life was derived from Scheringer et al. (2006).   
Scheringer et al. (2006) purposed the air half-life of <2 days as a screening 
criterion for chemical degradability in air.  The selection of an air half-life 
of 2 days was based, in part, on the distance traveled by a chemical in the 
air.  Scheringer et al. (2006) used the AOPWINTM estimation software to 
estimate the air half-life of organic chemicals that do not have measured 
rate constants.  AOPWINTM estimates chemical atmospheric oxidation 
potential, and is currently used for the European Union’s registration, 
evaluation and authorization of chemicals (REACH) program.  The air 
half-life for the six uncurated constituents was derived using the 
AOPWINTM model obtained from the Environmental Protection Agency’s 
EPIsuiteTM available on the ChemSpider website.  The biodegradability 
for the six uncurated constituents was derived using the BIOWINTM model 
obtained from the Environmental Protection Agency’s EPIsuiteTM 
available on the ChemSpider website.  BIOWINTM estimates the chemical 
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biodegradability.  The ACC in the 2011 Chemical Prioritization Screening 
Approach (ACC, 2011) suggests the use of the AOPWINTM and 
BIOWINTM models.   
To assess for bio-concentration, the bi- concentration factor (BCF), 
from the ACD/Labs Percepta Platform—Software Modules was used.  The 
ACD/Labs Percepta Platform—Software Modules predict 
physicochemical, ADME, and toxicity properties from chemical structure. 
ACD/BCF was accessed through the ChemSpider website.  In order to 
classify constituents as a bio-concentrator, a chemical must produce a bio-
concentration factor (BCF) > 5000.  The biodegradable, half-life, 
persistency, and bio-concentration factors for the six uncurated 
constituents can be viewed in Table 10.     
Based on the above recommendations, the six uncurated 
constituents were grouped with regard to persistence and bio-
concentration according to the factors in Table 11.  As demonstrated in 
Table 11, each constituent was assigned a numerical score based upon the 
constituent’s overall ranking.  The uncurated constituent persistency and bio-
concentration scores can be seen in Table 14.  The six uncurated 
chemicals were then grouped with regard to human health hazards and the 
factors found in Table 12.  As demonstrated in Table 12, each constituent 
was assigned a numerical score based upon the constituent’s ranking.  The 
human health hazards scores can be seen in Table 14.  The persistence and 
bio-concentration scores and the human health hazards score were summed 
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to derive an overall final score or value.  These values were then separated 
into categories from low to high and given a priority level.  The final score 
and priority level for the six uncurated burn pit constituents can be seen in 
Table 14. 
According to the priority level identified in Table 14, salicylaldehyde 
and triphenylene should be the first of the six constituents to require 
additional sampling and testing.  The second group to obtain additional 
sampling and evaluation are benzanthrone and n-octane.  The last group to 
attain further assessment is 4-ethyltoluene and n-heptane.  
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Table 10: Uncurated constituent human health hazard classification criteria 
Constituent Adapted from ACC Human Health Hazard Classification Criteria R2 
Toxicity 
 
Carcinogen  Insufficient  
Chemical 
Information  
Biodegradable  
 
½ 
life 
(days) 
Bio-
concentration 
Factor 
(BCF) 
Persistency 
VP 
(Pa) 
 
 
 
 
EDC 
60/20/20 70/15/15 80/10/10 
Acute 
 
Chronic 
 
4-ethyltoluene --- --- --- Yes No 4.9 No (451) No (0.67) No 0.10 
 
0.85 
 
0.96 
 
Benzanthrone --- Yes  --- Yes No - No (2350) No (0.67) Yes 0.75* 
 
0.84 
 
0.88 
 
n-Heptane Yes Yes No Not tested for 
Carcinogenicity 
Yes  5.5 No (1502) No 
(0.00003) 
No 0.94 
 
0.98 
 
0.70 
 
n-Octane Yes Yes No Yes Yes 6.4 No (3825) Yes (6133) No 0.02* 
 
1.00* 
 
0.96 
 
Salicylaldehyde --- --- --- Yes Yes - No (10 – 11) Yes (1880) Yes 1.00* 
 
1.00 
 
1.00 
 
Triphenylene  --- --- Possible 
Mutagen 
Yes No 344 Yes (13349) No (79) No 1.00* 
 
1.00 
 
1.00 
 
Note: Properties obtained from ChemSpider http://www.chemspider.com 
(---) Denotes no information available 
(-) Denotes incompatibility with BIOWIN Model  
(*) Denotes negative linearity 
 
 
 
 
 
 
          
94 
Table 11: Persistence and bio-concentration exposure ranking 
Persistence and Bio-concentration Ranking Persistence and Bio-concentration 
Score 
Not Persistent and No Bio-concentration Low 1 
Persistent and No Bio-concentration 
OR 
Bio-concentration and Not Persistent 
Medium 
  
3  
Persistent and Bio-concentration High 5 
 
Table 12: Human health hazard ranking 
Human Health  Ranking Health Ranking Score 
Non-Carcinogen with Acute Toxicity Medium 2 
Non-Carcinogen with Chronic Toxicity Medium 2 
Non-Carcinogen w/ Acute & Chronic 
Toxicity 
Medium -High 3 
Insufficient Data to Classify High 4 
Carcinogen No ranking add 1 to final score 1 
EDC Chemical  No ranking add 1 to final score 1 
 
Table 13: Integration of exposure rankings 
Combined Score  Exposure Ranking  Priority 
2 – 4 Low Low 
5 – 7 Medium Medium 
8 – 10 High High 
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Table 14: Uncurated constituent proposed prioritization  
 
Constituent 
Adapted from ACC Human Health Hazard Classification Criteria 
Persistence and Bio-concentration  Human Health Carcinogen EDC Final Score Priority 
4-ethyltoluene 1 4 - - 5 Low 
Benzanthrone 1 4 - 1 6 Med 
n-Heptane 1 3 - - 4 Low 
n-Octane 3 3 - - 6 Med 
Salicylaldehyde 3 4 - 1 8 High 
Triphenylene  3 4 1 - 8 High 
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V.  Conclusions and Recommendations 
Conclusions and Recommendations 
1. Misidentification rates of 73% or greater were observed for ANN simulations 
when the hidden layer size varied between 1 and 5.  The ANN model, as 
currently constructed and trained, does not have the predictive capability 
needed to screen constituents associated with burn pit emissions.  The number 
of hidden layers had little effect on the performance of the model.  Additional 
data is needed to train the model. 
2. Misidentification rates of 75% or greater were observed for ANN simulations 
when the TVT ratios ranged from 60/20/20 to 80/10/10 for the nine uncurated 
test constituents.  As currently constructed and trained, the ANN model does 
not have the predictive capability needed to screen burn pit emission 
constituents. The TVT ratios had little effect on the performance of the model, 
and are likely due to the need for additional training data. 
3. ANN-based screening of similar structured constituents containing benzene 
rings and hydrocarbon chains produced misidentification rates of 73% or 
greater, and R2 values of 0.0762 and lower.  The misidentification rates for 
similar structure constituents were lower than those misidentification rates 
observed for the original test set, while the R2 values for similar structure 
constituents were higher than the R2 values observed for the original test set. 
4. Further testing is recommended for several constituents with R2 values greater 
than 0.8.  The constituents with an R2 value greater than 0.8 include 4-
ethyltoluene, benzanthrone, n-heptane, n-octane, salicylaldehyde, and 
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triphenylene.  These constituents have been prioritized to help further develop 
predictive ANN models for human health force support.  Salicylaldehyde and 
triphenylene should be the first constituents to acquire additional sampling 
and testing, followed by benzanthrone and n-octane, and 4-ethyltoluene and n-
heptane.   
5. Evaluation of alternative disease categorization approaches is needed to 
determine the impact of disease categorization of the model’s performance.   
6. Reclassifying the training and testing data from categorical variable to 
continuous variables is needed to validate the chemical-diseases mapping 
provided by the Brouch model.  
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Appendix A 
Figure 7: TVT Comparison HL =1 
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Figure 8: TVT Comparison HL =2 
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Figure 9: TVT Comparison HL =3 
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Figure 10: TVT Comparison HL =4 
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Figure 11: TVT Comparison HL =5 
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Appendix B  
Figure 12: 4-Ethyltoluene 
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Figure 14: Benzyl Chloride 
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Figure 15: n-Heptane 
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Figure 16: n-Octane 
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Figure 17: Propene 
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Figure 18: Salicylaldehyde 
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Figure 19: Tetrahydrofuran 
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Figure 20: Triphenylene 
-5
0
5
10
15
20
25
0 5 10 15 20 25A
N
N
 P
re
di
ct
ed
 D
ise
as
e 
C
at
eg
or
y 
Actual Disease Category 
Triphenylene     
80/10/10 70/15/15 60/20/20 1:1 Reference Line
80/10/10 70/15/15 60/20/20
          
112 
Figure 21: Vinyl Acetate 
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Appendix C 
Table 15: ANN Training Data 
Chemical Name  Molecular Weight 
(UU) 
Hydrogen Acceptors 
 (VV) 
Hydrogen Donors  
(WW) 
Disease Category  
(ZZ) 
Acetone 58.08 1 0 9 
58.08 1 0 12 
58.08 1 0 15 
58.08 1 0 16 
58.08 1 0 17 
58.08 1 0 25 
Aciclovir 225.21 8 4 2 
225.21 8 4 3 
225.21 8 4 4 
225.21 8 4 5 
225.21 8 4 8 
225.21 8 4 9 
225.21 8 4 11 
225.21 8 4 12 
225.21 8 4 13 
225.21 8 4 15 
225.21 8 4 16 
225.21 8 4 17 
225.21 8 4 19 
225.21 8 4 20 
225.21 8 4 21 
225.21 8 4 23 
225.21 8 4 24 
225.21 8 4 25 
225.21 8 4 26 
Alprazolam 308.77 4 0 3 
308.77 4 0 4 
308.77 4 0 5 
308.77 4 0 7 
308.77 4 0 8 
308.77 4 0 9 
308.77 4 0 11 
308.77 4 0 12 
308.77 4 0 13 
308.77 4 0 16 
308.77 4 0 21 
308.77 4 0 23 
308.77 4 0 25 
Ammonium Sulfate 132.14 4 2 3 
132.14 4 2 17 
132.14 4 2 22 
 Aspirin 180.16 4 1 2 
180.16 4 1 3 
180.16 4 1 4 
180.16 4 1 5 
180.16 4 1 6 
180.16 4 1 7 
180.16 4 1 8 
180.16 4 1 9 
180.16 4 1 10 
180.16 4 1 11 
180.16 4 1 12 
180.16 4 1 13 
180.16 4 1 14 
180.16 4 1 15 
180.16 4 1 16 
180.16 4 1 17 
 
 
Aspirin 
(continued) 
180.16 4 1 19 
180.16 4 1 21 
180.16 4 1 22 
180.16 4 1 23 
180.16 4 1 24 
180.16 4 1 25 
180.16 4 1 26 
180.16 4 1 27 
Atenolol 266.34 5 4 3 
266.34 5 4 4 
266.34 5 4 5 
266.34 5 4 7 
266.34 5 4 9 
266.34 5 4 11 
266.34 5 4 12 
266.34 5 4 13 
266.34 5 4 14 
266.34 5 4 15 
266.34 5 4 16 
266.34 5 4 17 
266.34 5 4 21 
266.34 5 4 23 
266.34 5 4 24 
266.34 5 4 25 
Azithromycin 749.00 14 5 2 
749.00 14 5 3 
749.00 14 5 5 
749.00 14 5 7 
749.00 14 5 8 
749.00 14 5 9 
749.00 14 5 10 
749.00 14 5 11 
749.00 14 5 12 
749.00 14 5 13 
749.00 14 5 14 
749.00 14 5 15 
749.00 14 5 16 
749.00 14 5 17 
749.00 14 5 19 
749.00 14 5 21 
749.00 14 5 22 
749.00 14 5 23 
749.00 14 5 24 
749.00 14 5 24 
749.00 14 5 26 
Benzene 78.12 0 0 1 
78.12 0 0 3 
78.12 0 0 4 
78.12 0 0 5 
78.12 0 0 7 
78.12 0 0 9 
78.12 0 0 10 
78.12 0 0 11 
78.12 0 0 14 
78.12 0 0 15 
78.12 0 0 16 
78.12 0 0 17 
78.12 0 0 18 
78.12 0 0 21 
78.12 0 0 22 
78.12 0 0 23 
78.12 0 0 25 
78.12 0 0 27 
Benzyl-penicillin 334.40 6 2 1 
 
 
Benzyl-penicillin 
(continued) 
334.40 6 2 2 
334.40 6 2 3 
334.40 6 2 4 
334.40 6 2 5 
334.40 6 2 7 
334.40 6 2 8 
334.40 6 2 9 
334.40 6 2 10 
334.40 6 2 11 
334.40 6 2 12 
334.40 6 2 14 
334.40 6 2 16 
334.40 6 2 17 
334.40 6 2 19 
334.40 6 2 20 
334.40 6 2 21 
334.40 6 2 22 
334.40 6 2 23 
334.40 6 2 24 
334.40 6 2 25 
334.40 6 2 26 
Caffeine 194.19 6 0 1 
194.19 6 0 2 
194.19 6 0 3 
194.19 6 0 4 
194.19 6 0 5 
194.19 6 0 7 
194.19 6 0 8 
194.19 6 0 9 
194.19 6 0 10 
194.19 6 0 11 
194.19 6 0 12 
194.19 6 0 13 
194.19 6 0 14 
194.19 6 0 15 
194.19 6 0 16 
194.19 6 0 17 
194.19 6 0 19 
194.19 6 0 21 
194.19 6 0 22 
194.19 6 0 23 
194.19 6 0 25 
194.19 6 0 27 
Candoxatril 515.65 8 2 3 
515.65 8 2 7 
515.65 8 2 16 
515.65 8 2 17 
Carbamazepine 236.28 3 2 1 
236.28 3 2 3 
236.28 3 2 4 
236.28 3 2 5 
236.28 3 2 7 
236.28 3 2 8 
236.28 3 2 9 
236.28 3 2 10 
236.28 3 2 11 
236.28 3 2 12 
236.28 3 2 13 
236.28 3 2 14 
236.28 3 2 15 
236.28 3 2 16 
236.28 3 2 17 
236.28 3 2 19 
236.28 3 2 21 
 
 
Carbamazepine 
(continued) 
236.28 3 2 22 
236.28 3 2 23 
236.28 3 2 24 
236.28 3 2 25 
236.28 3 2 26 
Caustic Soda 40.00 1 1 1 
40.00 1 1 5 
40.00 1 1 19 
40.00 1 1 22 
40.00 1 1 27 
Chloramphenicol 323.14 7 3 2 
323.14 7 3 3 
323.14 7 3 5 
323.14 7 3 8 
323.14 7 3 9 
323.14 7 3 10 
323.14 7 3 11 
323.14 7 3 12 
323.14 7 3 14 
323.14 7 3 15 
323.14 7 3 16 
323.14 7 3 17 
323.14 7 3 19 
323.14 7 3 21 
323.14 7 3 22 
323.14 7 3 23 
323.14 7 3 25 
Cimetidine 252.34 6 3 2 
252.34 6 3 3 
252.34 6 3 4 
252.34 6 3 5 
252.34 6 3 7 
252.34 6 3 8 
252.34 6 3 9 
252.34 6 3 11 
252.34 6 3 12 
252.34 6 3 13 
252.34 6 3 14 
252.34 6 3 15 
252.34 6 3 16 
252.34 6 3 17 
252.34 6 3 19 
252.34 6 3 21 
252.34 6 3 22 
252.34 6 3 23 
252.34 6 3 24 
252.34 6 3 25 
252.34 6 3 26 
252.34 6 3 27 
Clonidine 230.10 3 2 3 
230.10 3 2 4 
230.10 3 2 5 
230.10 3 2 7 
230.10 3 2 8 
230.10 3 2 9 
230.10 3 2 11 
230.10 3 2 12 
230.10 3 2 13 
230.10 3 2 14 
230.10 3 2 16 
230.10 3 2 17 
230.10 3 2 19 
230.10 3 2 21 
230.10 3 2 22 
 
 
Clonidine 
(continued) 
230.10 3 2 23 
230.10 3 2 24 
230.10 3 2 25 
Copper Sulfate 159.61 4 0 4 
159.61 4 0 5 
159.61 4 0 9 
159.61 4 0 12 
159.61 4 0 13 
159.61 4 0 14 
159.61 4 0 16 
159.61 4 0 17 
159.61 4 0 19 
159.61 4 0 21 
159.61 4 0 22 
159.61 4 0 25 
Cyclosporine 1202.64 23 5 1 
1202.64 23 5 2 
1202.64 23 5 3 
1202.64 23 5 4 
1202.64 23 5 5 
1202.64 23 5 7 
1202.64 23 5 8 
1202.64 23 5 9 
1202.64 23 5 10 
1202.64 23 5 11 
1202.64 23 5 12 
1202.64 23 5 13 
1202.64 23 5 14 
1202.64 23 5 15 
1202.64 23 5 16 
1202.64 23 5 17 
1202.64 23 5 19 
1202.64 23 5 20 
1202.64 23 5 21 
1202.64 23 5 22 
1202.64 23 5 23 
1202.64 23 5 25 
1202.64 23 5 26 
Desipramine 266.39 2 1 2 
266.39 2 1 3 
266.39 2 1 4 
266.39 2 1 5 
266.39 2 1 7 
266.39 2 1 8 
266.39 2 1 9 
266.39 2 1 11 
266.39 2 1 12 
266.39 2 1 13 
266.39 2 1 15 
266.39 2 1 16 
266.39 2 1 17 
266.39 2 1 21 
266.39 2 1 22 
266.39 2 1 23 
266.39 2 1 25 
Dexamethasone 392.47 5 3 2 
392.47 5 3 3 
392.47 5 3 4 
392.47 5 3 5 
392.47 5 3 7 
392.47 5 3 8 
392.47 5 3 9 
392.47 5 3 10 
392.47 5 3 11 
 
 
Dexamethasone  
(continued) 
392.47 5 3 12 
392.47 5 3 13 
392.47 5 3 14 
392.47 5 3 15 
392.47 5 3 16 
392.47 5 3 17 
392.47 5 3 19 
392.47 5 3 20 
392.47 5 3 21 
392.47 5 3 22 
392.47 5 3 23 
392.47 5 3 24 
392.47 5 3 25 
392.47 5 3 26 
392.47 5 3 27 
Diazepam 284.75 3 0 2 
284.75 3 0 2 
284.75 3 0 4 
284.75 3 0 5 
284.75 3 0 8 
284.75 3 0 9 
284.75 3 0 11 
284.75 3 0 12 
284.75 3 0 13 
284.75 3 0 14 
284.75 3 0 15 
284.75 3 0 16 
284.75 3 0 17 
284.75 3 0 19 
284.75 3 0 21 
284.75 3 0 22 
284.75 3 0 23 
284.75 3 0 24 
284.75 3 0 25 
284.75 3 0 27 
Diclofenac 296.15 3 2 2 
296.15 3 2 3 
296.15 3 2 4 
296.15 3 2 5 
296.15 3 2 7 
296.15 3 2 8 
296.15 3 2 9 
296.15 3 2 11 
296.15 3 2 12 
296.15 3 2 13 
296.15 3 2 14 
296.15 3 2 15 
296.15 3 2 16 
296.15 3 2 17 
296.15 3 2 19 
296.15 3 2 21 
296.15 3 2 22 
296.15 3 2 23 
296.15 3 2 25 
296.15 3 2 26 
296.15 3 2 27 
Diltiazem-HCl 414.53 6 0 3 
414.53 6 0 4 
414.53 6 0 4 
414.53 6 0 7 
414.53 6 0 8 
414.53 6 0 9 
414.53 6 0 10 
414.53 6 0 11 
 
 
Diltiazem-HCl 
(continued) 
414.53 6 0 12 
414.53 6 0 13 
414.53 6 0 14 
414.53 6 0 15 
414.53 6 0 16 
414.53 6 0 17 
414.53 6 0 21 
414.53 6 0 23 
414.53 6 0 25 
Doxorubicin 543.53 12 7 1 
543.53 12 7 2 
543.53 12 7 3 
543.53 12 7 4 
543.53 12 7 5 
543.53 12 7 7 
543.53 12 7 8 
543.53 12 7 9 
543.53 12 7 10 
543.53 12 7 11 
543.53 12 7 12 
543.53 12 7 13 
543.53 12 7 14 
543.53 12 7 15 
543.53 12 7 16 
543.53 12 7 17 
543.53 12 7 19 
543.53 12 7 21 
543.53 12 7 22 
543.53 12 7 23 
543.53 12 7 24 
543.53 12 7 25 
543.53 12 7 26 
543.53 12 7 27 
Enalaprilat 376.46 7 2 3 
376.46 7 2 5 
376.46 7 2 21 
Erythromycin 733.95 14 5 1 
733.95 14 5 2 
733.95 14 5 3 
733.95 14 5 4 
733.95 14 5 5 
733.95 14 5 7 
733.95 14 5 8 
733.95 14 5 9 
733.95 14 5 10 
733.95 14 5 11 
733.95 14 5 12 
733.95 14 5 13 
733.95 14 5 14 
733.95 14 5 15 
733.95 14 5 16 
733.95 14 5 17 
733.95 14 5 19 
733.95 14 5 20 
733.95 14 5 21 
733.95 14 5 22 
733.95 14 5 23 
733.95 14 5 24 
733.95 14 5 25 
733.95 14 5 26 
Ethylene Glycol 62.07 2 2 4 
62.07 2 2 5 
62.07 2 2 9 
62.07 2 2 12 
 
 
Ethylene Glycol 
(continued) 
62.07 2 2 14 
62.07 2 2 16 
62.07 2 2 25 
Famotidine 337.45 9 8 3 
337.45 9 8 4 
337.45 9 8 5 
337.45 9 8 7 
337.45 9 8 9 
337.45 9 8 11 
337.45 9 8 12 
337.45 9 8 13 
337.45 9 8 14 
337.45 9 8 15 
337.45 9 8 16 
337.45 9 8 17 
337.45 9 8 21 
337.45 9 8 22 
337.45 9 8 23 
337.45 9 8 25 
337.45 9 8 26 
337.45 9 8 27 
Felodipine 384.26 5 1 3 
384.26 5 1 9 
384.26 5 1 12 
384.26 5 1 16 
384.26 5 1 21 
384.26 5 1 23 
384.26 5 1 24 
Ferric Chloride 162.20 0 0 3 
162.20 0 0 5 
162.20 0 0 9 
162.20 0 0 11 
162.20 0 0 12 
162.20 0 0 16 
162.20 0 0 21 
162.20 0 0 25 
162.20 0 0 27 
Fluorouracil 130.08 4 2 2 
130.08 4 2 3 
130.08 4 2 4 
130.08 4 2 5 
130.08 4 2 7 
130.08 4 2 8 
130.08 4 2 9 
130.08 4 2 10 
130.08 4 2 11 
130.08 4 2 12 
130.08 4 2 13 
130.08 4 2 14 
130.08 4 2 15 
130.08 4 2 16 
130.08 4 2 17 
130.08 4 2 19 
130.08 4 2 21 
130.08 4 2 22 
130.08 4 2 23 
130.08 4 2 24 
130.08 4 2 25 
130.08 4 2 26 
130.08 4 2 27 
Flurbiprofen 244.27 2 1 3 
244.27 2 1 4 
244.27 2 1 5 
244.27 2 1 8 
 
 
Flurbiprofen 
(continued) 
244.27 2 1 9 
244.27 2 1 11 
244.27 2 1 12 
244.27 2 1 13 
244.27 2 1 14 
244.27 2 1 15 
244.27 2 1 16 
244.27 2 1 17 
244.27 2 1 19 
244.27 2 1 21 
244.27 2 1 22 
244.27 2 1 23 
244.27 2 1 24 
244.27 2 1 25 
Formaldehyde 30.03 1 0 1 
30.03 1 0 1 
30.03 1 0 2 
30.03 1 0 3 
30.03 1 0 4 
30.03 1 0 5 
30.03 1 0 7 
30.03 1 0 8 
30.03 1 0 9 
30.03 1 0 11 
30.03 1 0 12 
30.03 1 0 13 
30.03 1 0 14 
30.03 1 0 15 
30.03 1 0 16 
30.03 1 0 18 
30.03 1 0 19 
30.03 1 0 20 
30.03 1 0 21 
30.03 1 0 22 
30.03 1 0 23 
30.03 1 0 24 
30.03 1 0 25 
30.03 1 0 26 
Furosemide 330.75 7 4 3 
330.75 7 4 4 
330.75 7 4 5 
330.75 7 4 7 
330.75 7 4 9 
330.75 7 4 10 
330.75 7 4 11 
330.75 7 4 12 
330.75 7 4 13 
330.75 7 4 14 
330.75 7 4 15 
330.75 7 4 16 
330.75 7 4 17 
330.75 7 4 19 
330.75 7 4 21 
330.75 7 4 22 
330.75 7 4 23 
330.75 7 4 25 
Gabapentin 30.03 1 0 27 
171.24 3 2 3 
171.24 3 2 4 
171.24 3 2 5 
171.24 3 2 7 
171.24 3 2 8 
171.24 3 2 9 
171.24 3 2 12 
 
 
Gabapentin 
(continued) 
171.24 3 2 13 
171.24 3 2 15 
171.24 3 2 16 
171.24 3 2 17 
171.24 3 2 21 
171.24 3 2 23 
171.24 3 2 24 
Glycerol 92.09 3 3 1 
92.09 3 3 3 
92.09 3 3 7 
92.09 3 3 8 
92.09 3 3 9 
92.09 3 3 12 
92.09 3 3 14 
92.09 3 3 16 
92.09 3 3 17 
92.09 3 3 21 
Hydrochloric Acid 36.46 0 1 2 
36.46 0 1 3 
36.46 0 1 4 
36.46 0 1 5 
36.46 0 1 7 
36.46 0 1 9 
36.46 0 1 11 
36.46 0 1 12 
36.46 0 1 13 
36.46 0 1 14 
36.46 0 1 15 
36.46 0 1 16 
36.46 0 1 17 
36.46 0 1 18 
36.46 0 1 19 
36.46 0 1 20 
36.46 0 1 21 
36.46 0 1 22 
36.46 0 1 23 
36.46 0 1 24 
36.46 0 1 25 
36.46 0 1 27 
Hydrochlorothiazide 297.74 7 4 3 
297.74 7 4 4 
297.74 7 4 5 
297.74 7 4 7 
297.74 7 4 9 
297.74 7 4 11 
297.74 7 4 12 
297.74 7 4 13 
297.74 7 4 14 
297.74 7 4 16 
297.74 7 4 17 
297.74 7 4 21 
297.74 7 4 22 
297.74 7 4 23 
297.74 7 4 24 
297.74 7 4 25 
Hydrofluoric Acid 20.01 1 1 5 
20.01 1 1 9 
20.01 1 1 12 
20.01 1 1 13 
20.01 1 1 14 
20.01 1 1 16 
20.01 1 1 17 
20.01 1 1 21 
20.01 1 1 22 
 
 
Hydrofluoric Acid 
(continued) 
20.01 1 1 24 
20.01 1 1 25 
20.01 1 1 27 
Ibuprofen 206.29 2 1 2 
206.29 2 1 3 
206.29 2 1 4 
206.29 2 1 5 
206.29 2 1 7 
206.29 2 1 8 
206.29 2 1 9 
206.29 2 1 10 
206.29 2 1 11 
206.29 2 1 12 
206.29 2 1 13 
206.29 2 1 14 
206.29 2 1 15 
206.29 2 1 16 
206.29 2 1 17 
206.29 2 1 19 
206.29 2 1 21 
206.29 2 1 22 
206.29 2 1 23 
206.29 2 1 24 
206.29 2 1 25 
206.29 2 1 26 
Imipramine 280.42 2 0 3 
280.42 2 0 4 
280.42 2 0 5 
280.42 2 0 7 
280.42 2 0 8 
280.42 2 0 9 
280.42 2 0 11 
280.42 2 0 12 
280.42 2 0 13 
280.42 2 0 14 
280.42 2 0 15 
280.42 2 0 16 
280.42 2 0 17 
280.42 2 0 19 
280.42 2 0 21 
280.42 2 0 22 
280.42 2 0 23 
280.42 2 0 24 
280.42 2 0 25 
Isopropyl Alcohol 60.10 1 1 2 
Itraconazole 705.65 12 0 2 
705.65 12 0 3 
705.65 12 0 4 
705.65 12 0 5 
705.65 12 0 7 
705.65 12 0 9 
705.65 12 0 11 
705.65 12 0 12 
705.65 12 0 13 
705.65 12 0 14 
705.65 12 0 15 
705.65 12 0 16 
705.65 12 0 17 
705.65 12 0 19 
705.65 12 0 20 
705.65 12 0 21 
705.65 12 0 22 
705.65 12 0 23 
705.65 12 0 25 
 
 
Ketoconazole 380.92 1 0 1 
380.92 1 0 2 
380.92 1 0 3 
380.92 1 0 4 
380.92 1 0 5 
380.92 1 0 7 
380.92 1 0 8 
380.92 1 0 9 
380.92 1 0 11 
380.92 1 0 12 
380.92 1 0 13 
380.92 1 0 14 
380.92 1 0 15 
380.92 1 0 16 
380.92 1 0 17 
380.92 1 0 20 
380.92 1 0 21 
380.92 1 0 22 
380.92 1 0 23 
380.92 1 0 24 
380.92 1 0 25 
380.92 1 0 27 
Ketoprofen 254.29 3 1 3 
254.29 3 1 4 
254.29 3 1 5 
254.29 3 1 9 
254.29 3 1 11 
254.29 3 1 12 
254.29 3 1 13 
254.29 3 1 14 
254.29 3 1 16 
254.29 3 1 21 
254.29 3 1 22 
254.29 3 1 23 
254.29 3 1 25 
254.29 3 1 27 
Labetalol-HCl 328.42 5 5 2 
328.42 5 5 3 
328.42 5 5 4 
328.42 5 5 4 
328.42 5 5 5 
328.42 5 5 7 
328.42 5 5 9 
328.42 5 5 11 
328.42 5 5 12 
328.42 5 5 13 
328.42 5 5 14 
328.42 5 5 15 
328.42 5 5 16 
328.42 5 5 17 
328.42 5 5 21 
328.42 5 5 22 
328.42 5 5 23 
328.42 5 5 25 
Lisinopril 405.50 8 5 3 
405.50 8 5 4 
405.50 8 5 5 
405.50 8 5 7 
405.50 8 5 8 
405.50 8 5 9 
405.50 8 5 11 
405.50 8 5 12 
405.50 8 5 13 
405.50 8 5 14 
 
 
Lisinopril 
(continued) 
405.50 8 5 16 
405.50 8 5 17 
405.50 8 5 21 
405.50 8 5 22 
405.50 8 5 23 
405.50 8 5 24 
405.50 8 5 25 
Magnesium Sulfate 120.37 4 0 2 
120.37 4 0 3 
120.37 4 0 4 
120.37 4 0 5 
120.37 4 0 8 
120.37 4 0 9 
120.37 4 0 11 
120.37 4 0 12 
120.37 4 0 13 
120.37 4 0 14 
120.37 4 0 16 
120.37 4 0 17 
120.37 4 0 21 
120.37 4 0 22 
120.37 4 0 25 
120.37 4 0 27 
Mannitol 182.18 6 6 3 
182.18 6 6 5 
182.18 6 6 7 
182.18 6 6 8 
182.18 6 6 9 
182.18 6 6 11 
182.18 6 6 12 
182.18 6 6 14 
182.18 6 6 15 
182.18 6 6 16 
182.18 6 6 17 
182.18 6 6 21 
182.18 6 6 22 
182.18 6 6 23 
182.18 6 6 24 
182.18 6 6 25 
182.18 6 6 26 
182.18 6 6 27 
Methotrexate 454.45 13 7 2 
454.45 13 7 3 
454.45 13 7 4 
454.45 13 7 4 
454.45 13 7 5 
454.45 13 7 7 
454.45 13 7 8 
454.45 13 7 9 
454.45 13 7 10 
454.45 13 7 11 
454.45 13 7 12 
454.45 13 7 13 
454.45 13 7 14 
454.45 13 7 15 
454.45 13 7 16 
454.45 13 7 17 
454.45 13 7 19 
454.45 13 7 21 
454.45 13 7 22 
454.45 13 7 23 
454.45 13 7 24 
454.45 13 7 25 
454.45 13 7 26 
 
 
Methotrexate (continued) 454.45 13 7 27 
Metoprolol-tartrate 267.37 4 2 3 
267.37 4 2 4 
267.37 4 2 5 
267.37 4 2 7 
267.37 4 2 8 
267.37 4 2 9 
267.37 4 2 11 
267.37 4 2 12 
267.37 4 2 13 
267.37 4 2 14 
267.37 4 2 15 
267.37 4 2 16 
267.37 4 2 17 
267.37 4 2 21 
267.37 4 2 22 
267.37 4 2 23 
267.37 4 2 24 
267.37 4 2 25 
267.37 4 2 27 
Nadolol 309.41 5 4 3 
309.41 5 4 5 
309.41 5 4 7 
309.41 5 4 11 
309.41 5 4 13 
309.41 5 4 16 
309.41 5 4 21 
309.41 5 4 23 
309.41 5 4 24 
309.41 5 4 25 
Naloxone 327.38 5 2 2 
327.38 5 2 3 
327.38 5 2 4 
327.38 5 2 5 
327.38 5 2 7 
327.38 5 2 8 
327.38 5 2 9 
327.38 5 2 10 
327.38 5 2 11 
327.38 5 2 12 
327.38 5 2 13 
327.38 5 2 14 
327.38 5 2 15 
327.38 5 2 16 
327.38 5 2 17 
327.38 5 2 19 
327.38 5 2 21 
327.38 5 2 22 
327.38 5 2 23 
327.38 5 2 24 
327.38 5 2 25 
327.38 5 2 27 
Naproxen-sodium 230.27 3 1 2 
230.27 3 1 3 
230.27 3 1 4 
230.27 3 1 5 
230.27 3 1 7 
230.27 3 1 9 
230.27 3 1 11 
230.27 3 1 12 
230.27 3 1 13 
230.27 3 1 14 
230.27 3 1 16 
230.27 3 1 17 
 
 
Naproxen-sodium 
(continued) 
230.27 3 1 19 
230.27 3 1 21 
230.27 3 1 22 
230.27 3 1 23 
230.27 3 1 24 
230.27 3 1 25 
230.27 3 1 26 
230.27 3 1 27 
Nortriptylene-HCl 263.39 1 1 3 
263.39 1 1 4 
263.39 1 1 5 
263.39 1 1 8 
263.39 1 1 9 
263.39 1 1 12 
263.39 1 1 13 
263.39 1 1 16 
263.39 1 1 17 
263.39 1 1 19 
263.39 1 1 21 
263.39 1 1 22 
263.39 1 1 24 
263.39 1 1 25 
263.39 1 1 27 
Omeprazole 267.25 9 2 2 
267.25 9 2 3 
267.25 9 2 4 
267.25 9 2 5 
267.25 9 2 7 
267.25 9 2 8 
267.25 9 2 9 
267.25 9 2 11 
267.25 9 2 12 
267.25 9 2 13 
267.25 9 2 14 
267.25 9 2 15 
267.25 9 2 16 
267.25 9 2 17 
267.25 9 2 19 
267.25 9 2 20 
267.25 9 2 21 
267.25 9 2 22 
267.25 9 2 23 
267.25 9 2 24 
267.25 9 2 25 
Phenytoin 451.49 10 2 3 
451.49 10 2 4 
451.49 10 2 5 
451.49 10 2 7 
451.49 10 2 8 
451.49 10 2 9 
451.49 10 2 10 
451.49 10 2 11 
451.49 10 2 12 
451.49 10 2 13 
451.49 10 2 14 
451.49 10 2 15 
451.49 10 2 16 
451.49 10 2 17 
451.49 10 2 19 
451.49 10 2 21 
451.49 10 2 22 
451.49 10 2 23 
451.49 10 2 24 
451.49 10 2 25 
 
 
Phenytoin 
(continued) 
451.49 10 2 26 
451.49 10 2 27 
Piroxicam 331.35 7 2 3 
331.35 7 2 4 
331.35 7 2 5 
331.35 7 2 8 
331.35 7 2 9 
331.35 7 2 11 
331.35 7 2 12 
331.35 7 2 14 
331.35 7 2 15 
331.35 7 2 16 
331.35 7 2 17 
331.35 7 2 19 
331.35 7 2 21 
331.35 7 2 22 
331.35 7 2 23 
331.35 7 2 25 
331.35 7 2 26 
331.35 7 2 27 
Potassium Bromide 119.00 1 0 16 
Potassium Permangante 158.03 4 0 5 
Prazosin 383.41 9 2 3 
383.41 9 2 4 
383.41 9 2 5 
383.41 9 2 7 
383.41 9 2 8 
383.41 9 2 9 
383.41 9 2 11 
383.41 9 2 12 
383.41 9 2 13 
383.41 9 2 14 
383.41 9 2 15 
383.41 9 2 16 
383.41 9 2 17 
383.41 9 2 21 
383.41 9 2 23 
383.41 9 2 25 
Propranolol-HCl 259.35 3 2 3 
259.35 3 2 4 
259.35 3 2 5 
259.35 3 2 7 
259.35 3 2 8 
259.35 3 2 9 
259.35 3 2 11 
259.35 3 2 12 
259.35 3 2 13 
259.35 3 2 14 
259.35 3 2 15 
259.35 3 2 16 
259.35 3 2 17 
259.35 3 2 19 
259.35 3 2 21 
259.35 3 2 22 
259.35 3 2 23 
259.35 3 2 24 
259.35 3 2 25 
259.35 3 2 27 
Quinidine 324.43 4 1 3 
324.43 4 1 4 
324.43 4 1 5 
324.43 4 1 8 
324.43 4 1 9 
324.43 4 1 10 
 
 
Quinidine 
(continued) 
324.43 4 1 11 
324.43 4 1 12 
324.43 4 1 13 
324.43 4 1 14 
324.43 4 1 16 
324.43 4 1 17 
324.43 4 1 19 
324.43 4 1 20 
324.43 4 1 21 
324.43 4 1 22 
324.43 4 1 23 
324.43 4 1 25 
Ranitidine-HCl 314.41 7 2 2 
314.41 7 2 3 
314.41 7 2 3 
314.41 7 2 5 
314.41 7 2 7 
314.41 7 2 8 
314.41 7 2 9 
314.41 7 2 11 
314.41 7 2 12 
314.41 7 2 13 
314.41 7 2 14 
314.41 7 2 15 
314.41 7 2 16 
314.41 7 2 17 
314.41 7 2 19 
314.41 7 2 21 
314.41 7 2 22 
314.41 7 2 23 
314.41 7 2 24 
314.41 7 2 25 
314.41 7 2 26 
314.41 7 2 27 
Silver Nitrate 169.87 3 0 11 
Sodium Thiosulfate 158.11 4 0 9 
158.11 4 0 12 
158.11 4 0 16 
158.11 4 0 17 
158.11 4 0 19 
158.11 4 0 25 
Tenidap 320.76 5 2 9 
320.76 5 2 11 
320.76 5 2 12 
320.76 5 2 14 
320.76 5 2 23 
Terfenadine 471.69 3 2 3 
471.69 3 2 4 
471.69 3 2 5 
471.69 3 2 9 
471.69 3 2 11 
471.69 3 2 12 
471.69 3 2 14 
471.69 3 2 15 
471.69 3 2 16 
471.69 3 2 17 
471.69 3 2 19 
471.69 3 2 21 
471.69 3 2 22 
471.69 3 2 23 
471.69 3 2 25 
Testosterone 288.43 2 1 1 
288.43 2 1 3 
288.43 2 1 4 
 
 
Testosterone 
(continued) 
288.43 2 1 5 
288.43 2 1 7 
288.43 2 1 9 
288.43 2 1 10 
288.43 2 1 11 
288.43 2 1 12 
288.43 2 1 13 
288.43 2 1 15 
288.43 2 1 16 
288.43 2 1 17 
288.43 2 1 19 
288.43 2 1 20 
288.43 2 1 21 
288.43 2 1 22 
288.43 2 1 23 
288.43 2 1 25 
288.43 2 1 26 
288.43 2 1 27 
Trovafloxacin 416.36 7 3 2 
416.36 7 3 3 
416.36 7 3 5 
416.36 7 3 9 
416.36 7 3 12 
416.36 7 3 14 
416.36 7 3 16 
416.36 7 3 21 
416.36 7 3 25 
Valproic-acid 144.22 2 1 1 
144.22 2 1 3 
144.22 2 1 4 
144.22 2 1 5 
144.22 2 1 7 
144.22 2 1 8 
144.22 2 1 9 
144.22 2 1 10 
144.22 2 1 11 
144.22 2 1 12 
144.22 2 1 13 
144.22 2 1 14 
144.22 2 1 15 
144.22 2 1 16 
144.22 2 1 17 
144.22 2 1 19 
144.22 2 1 21 
144.22 2 1 22 
144.22 2 1 23 
144.22 2 1 24 
144.22 2 1 25 
144.22 2 1 27 
Vinblastine 811.00 13 3 2 
811.00 13 3 3 
811.00 13 3 4 
811.00 13 3 5 
811.00 13 3 7 
811.00 13 3 8 
811.00 13 3 9 
811.00 13 3 10 
811.00 13 3 11 
811.00 13 3 12 
811.00 13 3 13 
811.00 13 3 14 
811.00 13 3 15 
811.00 13 3 16 
811.00 13 3 17 
 
 
Vinblastine 
(continued) 
811.00 13 3 19 
811.00 13 3 21 
811.00 13 3 22 
811.00 13 3 23 
811.00 13 3 24 
811.00 13 3 25 
811.00 13 3 26 
Zinc Chloride 136.29 0 0 5 
136.29 0 0 13 
136.29 0 0 15 
136.29 0 0 21 
136.29 0 0 25 
Ziprasidone 412.95 5 1 3 
412.95 5 1 4 
412.95 5 1 5 
412.95 5 1 7 
412.95 5 1 11 
412.95 5 1 13 
412.95 5 1 14 
412.95 5 1 16 
412.95 5 1 19 
412.95 5 1 21 
412.95 5 1 22 
412.95 5 1 23 
412.95 5 1 25 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix D 
Table 16: ANN Testing Data 
Chemical 
Name  
Molecular 
Weight 
(CC) 
Hydrogen 
Acceptors 
(DD) 
Hydrogen 
Donors 
(EE) 
ANN 
Derived 
Disease 
(60/20/20)                   
ANN  
Rounded 
Disease 
(60/20/20) 
ANN 
Derived 
Disease 
(70/15/15)                   
ANN  
Rounded 
Disease 
(70/15/15) 
ANN 
Derived 
Disease   
(80/10/10)                 
ANN  
Rounded 
Disease 
(80/10/10)  
Known 
Disease 
Category 
 (II) 
4-Ethyltoluene 
(622-96-8) 
120.19 0 0 7.09 7 8.92 9 4.966 5 16 
120.19 0 0 2.35 5 11.89 12 6.62 7 22 
120.19 0 0 17.43 17 14.87 15 8.27 8 23 
Benzanthrone 
(82-05-3) 
230.26 1 0 10.56 11 4.5 5 8.11 8 5 
230.26 1 0 -2.21 -2 6 6 10.81 11 9 
230.26 1 0 -2.67 -3 7.5 8 13.52 14 12 
230.26 1 0 -2.64 -3 8 8 14.42 14 23 
Salicylaldehyde 
(90-02-8) 
122.12 2 1 6.37 6 8.5 9 6.4 6 7 
122.12 2 1 -5.76 -6 11.33 11 9.46 9 23 
Benzyl Chloride                         
(100-44-7) 
156.58 0 0 10.56 11 4.5 5 8.12 8 8 
156.58 0 0 -2.21 -2 6 6 10.83 11 15 
156.58 0 0 -2.67 -3 7.5 8 13.54 14 22 
n-Heptane                             
(142-82-5) 
100.20 0 0 3.35 3 4.5 5 5.36 5 3 
100.20 0 0 10.54 11 5.9 6 7.14 7 5 
100.20 0 0 11.27 11 7.3 7 8.93 9 16 
100.20 0 0 13.68 14 7.77 8 9.52 10 22 
100.20 0 0 15.14 15 8.24 8 10.12 10 23 
n-Octane                             
(Octane) 
(111-65-9) 
114.22 0 0 4.19 4 2.24 2 7.32 7 16 
114.22 0 0 0.60 1 0.51 1 11.1 11 22 
114.22 0 0 3.36 3 -1.22 0 14.85 15 23 
Propene 
(115-07-1) 
42.07 0 0 5.88 6 5.66 6 4.85 5 3 
42.07 0 0 7.22 7 7.55 8 6.47 6 5 
42.07 0 0 3.98 4 9.44 9 8.09 8 8 
42.07 0 0 15.84 16 10.07 10 8.63 9 16 
42.07 0 0 13.37 13 10.7 11 9.17 9 19 
42.07 0 0 18.61 19 15.73 16 13.48 13 22 
42.07 0 0 -0.02 -0.02 1.26 1 1.08 1 23 
Tetrahydrofuran                      
(109-99-9) 
72.10 1 0 7.09 7 8.92 9 4.98 5 3 
72.10 1 0 2.36 2 11.9 12 6.65 7 5 
72.10 1 0 17.43 17 14.87 15 8.31 8 8 
72.10 1 0 12.55 13 15.86 16 8.86 9 9 
72.10 1 0 8.55 9 16.86 17 9.42 9 12 
72.10 1 0 24.66 25 24.79 25 13.85 14 16 
72.10 1 0 0.64 1 1.98 2 1.1 1 22 
72.10 1 0 2.91 3 2.97 3 1.66 2 23 
Triphenylene            
(217-59-4) 
228.29 0 0 10.55 11 4.5 5 8.13 8 8 
228.29 0 0 -2.21 -2 6 6 10.84 11 23 
Vinyl Acetate 
(108-05-4) 
86.08 1 0 4.19 4 0.07 0 6.31 6 3 
86.08 1 0 0.60 1 0.09 0 8.42 8 5 
86.08 1 0 3.36 3 0.11 0 10.53 11 8 
86.08 1 0 2.27 2 0.11 0 11.23 11 9 
86.08 1 0 15.24 15 0.12 0 11.93 12 16 
86.08 1 0 20.61 21 0.17 0 17.55 18 19 
86.08 1 0 1.79 2 0.02 0 1.4 1 22 
86.08 1 0 -0.34 -0.3 0.03 0 2.1 2 23 
86.08 1 0 1.66 2 0.04 0 2.8 3 24 
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